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Biographical History:​ Karl E. Peace was born into a family of southwest Georgia 
sharecroppers in Baker County, Georgia, on July 28, 1941. He overcame an impoverished 
background to become immensely successful, both academically and professionally. 
In 1959, with a loan of $532 from a businessman in a neighboring county, he enrolled at 
Georgia Southern University, prepaying his tuition for the first two quarters. In the third 
quarter, he obtained a Georgia State Teacher’s scholarship that, in addition to his seven 
part-time jobs, helped him complete his bachelor’s degree in chemistry while supporting his 
siblings and cancer-stricken mother. He went on to earn a master’s degree in mathematics 
from Clemson University, teach at several colleges and universities, and earn a PhD in 
biostatistics from the Medical College of Virginia (MCV). 
 
Peace began to pursue a career in biostatistics in the pharmaceutical industry in 1978. After 
rising from an entry-level biostatistician position at Burroughs-Wellcome to vice president 
of 
worldwide technical operations at Parke-Davis/Warner Lambert, he started 
Biopharmaceutical Research Consultants Inc. in 1989. Dozens of international biotech and 
pharmaceutical companies relied on his expertise and he played a key role in the 
development and regulatory approval of dozens of medicines, including drugs used to treat 
Alzheimer’s disease, hypertension, arthritis, anxiety, depression and panic attacks, and 
gastrointestinal ulcers. At the same time, Peace kept one foot in the classroom, serving as 
an adjunct faculty member at Duke University, the MCV, the University of Michigan, The 
University of North Carolina, Temple University, and Virginia Commonwealth University. 
Peace approached Georgia Southern University officials in 1998 with a plan to establish a 
biostatistics center at the university, a corresponding program of study in biostatistics at the 
graduate level, and a school of public health.  
 
Peace returned to the Statesboro, Georgia, campus in the fall of 2000, when Georgia 
Southern began to offer the masters of public health degree in biostatistics that he and 
Charles Hardy developed. In 2004, his endowment to honor his late wife led to the creation 
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of the Jiann-Ping Hsu School of Public Health (JPHSOPH), the first school of public health in 
the University System of Georgia (USG). In creating the JPHSOPH, the board of regents also 
named the center for biostatistics the Karl E. Peace Center for Biostatistics. Peace made 
many contributions to the literature, publishing 10 books and more than 150 articles. 
 
Peace was the recipient of dozens of honors, awards, and citations, and he was 
internationally known as an educator, researcher, author, humanitarian, and philanthropist. 
For example, he was the 1998 Distinguished Alumnus of GSU; the 2003 GSU Alumnus of the 
Year in private enterprise; the first recipient of the President’s Medal at GSU in 2005; the 
2009 recipient of the GSU Award for Excellence in Research and Scholarly Activity; the 
Georgia Cancer Coalition’s Distinguished Cancer Scholar at GSU (a first for GSU) from 
2002–2007; the first recipient at GSU of a grant from the Georgia Research Alliance; the 
endower of the first Eminent Scholar Chair at GSU; the endower of the Karl E. Peace/JP Hsu 
Eminent Scholar Chair in Public Health at GSU; the endower of 13 scholarships at GSU; and a 
benefactor of the GSU library, Center for  Disabled Students, and the music and art 
departments. He was cited as Georgia Southern University’s greatest benefactor in the 2004 
Campaign for National Distinction. 
 
Additionally, Peace was the 1991 Star Alumnus of the MCV; the 2005 recipient of the MCV 
Founder’s Society Award; the 2007 recipient of the American Public Health Association 
(APHA) Statistics Section Award for his contributions to the pharmaceutical industry in drug 
research and development, the founder and editor-in-chief of the​ Journal of 
Biopharmaceutical Statistic​s; the founder of the Biopharmaceutical Applied Statistical 
Symposium (BASS); and the recipient of meritorious service awards from the American 
Society for Quality Control, Drug Information Association, BASS, Southwest Georgia Cancer 
Coalition, and Georgia Cancer Coalition.  
 
Peace endowed two scholarships at the University of California at Berkeley, including the 
JiannPing Hsu/Karl E. Peace Chair in Biostatistics; three scholarships in biostatistics at MCV; 
one scholarship at Randolph-Macon College; and the Jiann-Ping Hsu Biopharmaceutical 
and Regulatory Sciences Session at the annual meeting of the International Chinese 
Statistical Association. He was also a major contributor to the growth of the Philippine 
Statistical Association and responsible for creating the Office of the International Chinese 





Scope and Content: ​This collection consists of the personal and research papers of Karl E. 
Peace, Professor of Biostatistics at Georgia Southern University and namesake of the Karl E. 
Peace Center for Biostatistics and Survey Research. Materials span 1941to 2018 and include, 
correspondence, teaching materials, published articles, and manuscripts. A small portion of 
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The collection has been tentatively sorted into three main categories, manuscripts, teaching 
and research.  
 







































Acquisitions Info​: Donated by Karl E. Peace, 2012 - 2018. 
 
Access Points:  
Biology -- Study and teaching -- Sources 
Biometry -- Study and teaching -- Sources 
Biopharmaceutics -- Study and teaching -- Sources 
Biology -- Study and teaching 

















BASS XI: Short Courses 
● Lecture 00: 
○ Data Mining Introduction 
● Lecture 01: 
○ All linear Statistical Methods are Special Cases of 
SVD 
● Lecture 02: 
○ Data Mining of Large, Clinical Trials 
● Lecture 04: 
○ Multiple Trees and Metabolomic Data 
● Lecture 06: 
○ Multiple Blocks of Data rSVD and RP 
○ Subgroup Analysis of Clinical Trials 
○ Recursive Partitioning with a Multivariate 
Dependent 
○ Lecture Notes 




● BASS XI: “A Brief for Breaking our Rules” 
● Breast Cancer Chemotherapy Treatment, Design, and 
Recent Advances 
● Determination of the Best Linear Unbiased Estimates 
(Blue) of Incomplete Data For The Analysis of Repeated 
Measurements In Clinical Trials 
● Endpoints in HIV/AIDS Clinical Trials 
● Lecture 04: 
○ Multiple Trees and Metabolomic Data 
● Lecture 06: 
○ Multiple Blocks of Data rSVD and RP 
● Subgroup Analysis of Clinical Trials 
● Recursive Partitioning with a Multivariate Dependent 
● Lecture Notes 
● Design and Interim Monitoring of Flexible Clinical Trials 
● Statistical Considerations in Biomarker Method 
Development & Validation 
1  2 
BASS XI: Tutorials continued 
● Non-inferiority Trials -Hypotheses and Analyses 
● Active Control Non-Inferiority Trial- The Hypothesis 
● Multiple Primary Endpoints in Clinical Trials 
● Optimal Adaptive vs. Optimal Group Sequential Designs 
1  3 
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● Methods for Incorporating Flexibility in Clinical Trials 
● Using Robust Parameter Design In Industrial Experiments 
● Critical Path: An Overview 
● Emerging Issues and Considerations in Clinical Trial 
Design Strategy for Drug Development 
● Emerging Issues and Considerations in Manufacturing 
Quality Control and Assurance of Drug Products 
BASS XIII: Short courses, Nov. 06 
● Statistical Methods to Address Multiplicity: 
○  Adaptive Designs and the One Study Paradigm 
versus the Two (or More) Studies Paradigm as the 
Primary Confirmatory Evidence for a New Medical 
Product Relative to a Control 
● Statistical Methods to Address Multiplicity: 
○  Statistical Considerations for the Conduct and 
Reporting of Interim Analyses 
● Statistical Methods to Address Multiplicity: 
○  Analyses for Sub-population Effects 
● Statistical Methods to Address Multiplicity: 
○  Discussion of Applications of SAS Macros for 
Multiplicity Adjustment 
● Statistical Methods to Address Multiplicity: 
○  Analysis of Covariance: Parametric and 
Nonparametric 
● Statistical Methods to Address Multiplicity: 
○  Methods for Multiple Group Comparisons Bass 
● Statistical Methods to Address Multiplicity: 
○  Overview for Issues and Methods for Multiple 
Endpoints 
● Statistical Methods to Address Multiplicity: 
○  Summary and Discussions for Points to Consider 
and Guidance for Multiplicity, Missing Data, and 
Adjustment for Baseline Covariates 
● Adaptive Design Methods in Clinical Trials 
● Statistical Methods to Address Multiplicity: 
○  Discussion of Application of the MULTTEST 
Procedure in SAS 
● BASS XIII: Course Schedule 
1  4 
BASS XIII: Short courses continued Nov.06 
● Conditional Inference 
● Improving Statisticians’ Consulting Effectiveness 
● Using The Myers-Briggs Type Indicator 
● Improving One-On-One Communications Skills 
● Improving Group Communications 
● Chapter 1. The Babel Problem, The Partnering Solution 
1  5 
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BASS XIII: Stat Symposium, Nov. 06 
● BASS XIII Thirteenth Annual Biopharmaceutical Applied 
Statistics Symposium 
● Simulation for Designing and Analyzing Clinical Trials 
● Comparison of Statistical Analysis Methods Using 
Modeling and Simulation for Modern Protocol Design 
● Design of Dose Response Clinical Trials 
● Resampling Based Multiple Testing 
● BASS XIII Insightful 
● Model Based Adaptive Dose Ranging Designs 
● Bioequivalence trials designed using adaptive 
methodologies 
1  6 
BASS XIII: Stat Symposium continued 
● A Comparison of Methods for Longitudinal Data with 
Missing Due to Truncation 
● Rescue Behavior and Imputation Strategies in Analgesic 
Studies 
● Multivariate Assays with Values Below the Lower Limit of 
Quantitation: 
○  Parametric Estimation by Imputation and 
Maximum Likelihood 
● Variability in Gene Expression in Healthy Volunteers 
● Adaptive Design Methods in Clinical Trials 
● Considerations in Planning and Testing for Multiple 
Endpoints in Clinical Trials 
● Issues and Considerations in Composite Endpoints 
● Recent Results Concerning Multiplicities in Animal 
Carcinogenicity Studies 
● Tree-structured gatekeeping procedures in clinical trials 
with multiple objectives 
● BASS XIII Fellows 
● BASS XIII letter from Karl E. Peace 
● Our Keynote Speaker is Greg Campbell 
● Letter to BASS Committee Members from Laura H. Gunn 
● Adaptive Design Methods in Clinical Trials 
● Housekeeping 
● Program Abstracts Conference Sessions 
1  7 
BASS XIV: Stat Symposium, Nov. 07 
● An Adaptive Dose Finding Design (DOSEFIND) Using a 
Nonlinear 
● Dose Response Model 
● Dose Response Analysis for Combination Products 
● Parametric Bayesian Dose Response Modeling 
● Concordance Analysis in Biopharmaceutical Industry 
● Statistical Validation of Surrogate Markers 
1  8 
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● An Introduction to Pathodynamics from the View of Liver 
Homeostasis Using the Ornstein-Uhlenbeck Process 
● On the Analysis of Longitudinal Clinical Lab Data with 
Latent Mixture Models 
● Some Thoughts on the Assessment of Pharmaceutical 
Safety Data 
● Statistical Modeling and Graphical Analysis of Safety Data 
in Clinical Trials 
● Absolute Risk: Clinical Applications and Controversies 
BASS XIV: Stat Symposium continued Nov.07 
● Adaptive Model-Based Designs in Clinical Drug 
Development 
● A Nonlinear Model Based Method for Steady-state 
Assessment 
● Moving Beyond QT… 
● Strategies for Meta-Analyses of Randomized Clinical 
Trials Based on Individual Patient Data 
● Statistical Issues in Predictive Toxicology 
● Enriching and Mining Missing Data: Design and Analysis 
Issues 
● Missing Data: The shape of things to come 
● An Overview of Causal Inference and its Application in 
Clinical Trials 
● Developing an Analytical Road Map for Incomplete 
Longitudinal Clinical Trial Data 
1  9 
BASS XIV: Stat methods for Biomarker Discovery, Nov. 07 
● Statistical Learning From Data 
● Prediction Methods 
● Super Learning 
● Super Learning in Prediction 
● Informative Censoring Addressing Bias in Effect Estimates 
Due To Study Drop-out 
● Assessing ETA Violations, and Selecting 
Attainable/Realistic Parameters 
● Targeted MLE for Variable Importance and Causal Effect 
with Clinical Trial/Randomized and Observational Data 
● Multiple Testing 
● Outline 
● Controlling FDR in Second Stage Analysis 
● Secondary Analysis 
● Resampling Based Multiple Testing 





BASS XIV: Stat Graph, Covariance Analysis, Nov. 07 
● Statistical Graphics 
● Statistical Problems to Document and to Avoid 
● How Should Change be Measured? 
● The Role of Covariable Adjustment in the Analysis of 
Clinical Trials 
● Bayesian Approaches to Design and Analysis of RCTs and 
Advantages over Frequentist Methods 
1  11 
BASS XV: Creating more effective graphs, Nov. 08 
● Creating More Effective Graphs 
● Creating More Effective Graphs with Applications to 
Clinical Trials and 
● Electronic Medical Records: 
○  Use of Advanced Computer Methods and 
Visualization Tools to Simplify the Analysis of 
Complex Clinical Drug Safety Data 
1  12 
BASS XV: Trial simulation, Nov. 08 
●  Lecture 1: Mathematical Modeling And Trial Simulation In 
Medicine And Life Sciences 
●  Lecture 2: Regulatory Aspects of Modeling And 
Simulation 
●  Lecture 3: Simulation For Designing And Analyzing 
Clinical Trials – A Statistical Approach 
●  Lecture 4: Simulation For Designing And Analyzing 
Clinical Trials – A Statistical Approach 
●  Lecture 5: Simulation For Designing And Analyzing 
Clinical Trials – A Statistical Approach 
●  Lecture 6: Simulation For Designing And Analyzing 
Clinical Trials – A Statistical Approach 
●  Lecture 7: Simulation For Designing And Analyzing 
Clinical Trials – A Statistical Approach 
●  Lecture 8: Simulation For Designing And Analyzing 
Clinical Trials – A Statistical Approach 
●  Lecture 9: Simulation For Designing And Analyzing 
Clinical Trials – A Statistical Approach 
●  Lecture 10: Simulation For Designing And Analyzing 
Clinical Trials – A Statistical Approach 
●  Lecture 11: Pharmacokinetic & Pharmacodynamic 
Concepts 
●  Lecture 12: Pharmacology, Pharmacokinetics & 
Pharmacodynamics 
●  Lecture 13: Modeling In Biopharmaceutics, PK and PD 
●  Lecture 14: Modeling In Biopharmaceutics, PK and PD 
●  Lecture 15: Modeling In Biopharmaceutics, PK and PD 
1  13 
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BASS XV: trial simulation continued 
● Lecture 16: Modeling In Biopharmaceutics, PK and PD 
● Lecture 17: Population Dynamics 
● Lecture 18: Population Dynamics 
● Lecture 18: Population Dynamics 
● Lecture 19: Population Dynamics 
● Lecture 20: Population Dynamics 
● Lecture 21: Epidemics 
● Lecture 22: Epidemics 
● Lecture 23: Epidemics 
● Lecture 24: Computational Neuroscience 
● Lecture 25: Computational Neuroscience 
● Lecture 26: Computational Neuroscience 
● Lecture 27: Computational Neuroscience 
● Lecture 28: Mathematical Modeling & Simulation 
● Lecture 29: Mathematical Modeling & Simulation 
● Lecture 30: Modeling Of the Human Heart 
● Lecture 31: Modeling Of the Human Heart 
● Lecture 32: Modeling Of the Human Heart 
1  14 
BASS XV: Cross-over Trials, Nov. 08 
● The Design and Analysis of Cross-over Trials 
1  15 
BASS XV: Fifteenth Annual Biopharmaceutical Applied Statistics 
Symposium 
1  16 
BASS XVI: Stat Symposium Nov.09 
● Controversial Issues in Clinical Trials 
● Dose-finding in oncology clinical trials based on unit 
probability mass 
● Implementing Response-Adaptive Randomization in 
Multi-Armed Survival Trials 
● Evaluating Probability of Success in Oncology Clinical 
Trials 
● Design and Analysis of a Cancer Prevention Trial: Plans 
and Results 
● Comparing Conditional and Predictive Power to Assess 
Futility in a Phase III Program with Two Studies 
● Comparing Conditional and Predictive Power to Assess 
Futility in a Phase III Program with Two Studies 
● Setting Alpha Levels for Testing Key Secondary 
Endpoints in Trials with Interim Assessments when the 
Primary and Secondary Endpoints are Correlated 
● Efficient Sampling of Inverse Correlation Matrices and its 
Applications in Bayesian Modeling of Gene Interaction in 
Early Phase Genomic Experiments 
● The Mean Ain’t What It Used to Be 
1  17 
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● Subgroup Data Analyses of Clinical Trials- Issues & 
Methods 
● Analyses to Aid Dose Selection in Ph 2 Virology Clinical 
Trials Larry F. Leon 
BASS XVI: Stat Symposium cont. Nov. 09 
● Phase 2a “Power” Calculations: Comparisons with SOC 
● Statistical Graphics for Exploratory Review and Reporting 
in Clinical Trials 
● Statistical assessment and analyses of suicidality data in 
clinical trials: current challenges 
● Retrospective Look: Logistics of Implementing a 
Suicidality Analysis 
● Using Statistical Principles to Implement FDA Guidance 
on Cardiovascular Risk Assessment for Diabetes Drugs 
● Lifecycle Planning For Safety Evaluation In Support Of 
Benefit-Risk Activities 
● On Methodologies Associated with Meta-analysis 
● Targeted Maximum Likelihood Super Learning: 
Application to Causal Effects in Safety Analysis 
● Letter from Laura H. Gunn to Bass Attendees 
● Bass XVI Fellows 
● Housekeeping 
● Bass XVI Attendees 
1  18 
BASS XVI: Bayesian Methods, Nov. 09 
● Recent Developments in Practical Bayesian Methods for 
Clinical Trials 
1  19 
BASS XVI: Fundamental Training, Nov. 09 
● The Development and Execution of a Clinical Program 
● Design of Dose Response Clinical Trials 
● The Roles of the (Bio) Statistician in Clinical Trials 
● Data Monitoring in Clinical Trials Using Prediction 
● Data Monitoring Committees 
● Planning and Reporting Your Analyses 
● Noninferiority Trials 
● Analysis of Efficacy 
● Subgroup Analysis 
● Benefit: Risk Assessment 
1  20 
BASS XVI: Bioequivalence & Statistics Nov. 09 
● Bioequivalence and Statistics in Clinical Pharmacology 
1  21 
BASS XVII: Genomics, Nov. 10 
● Introduction to Design of Genomic Clinical Trials 
● Targeted (Enrichment) Design 
1  22 
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BASS XVII: Tutorials, Nov. 10 
● Multiplicity problems in clinical trials A regulatory 
perspective 
● A Process View of Statistics for Clinical Trials: ANOVA, 
Product-Limit, and Adaptive Design 
● Covariate-Adjusted Response-Adaptive Randomization 
Designs for Phase III Survival Trials 
● Sample Size Re-estimation Using Adaptive Tests and 
Generalized Likelihood Ratio: A Comparative Study 
● Failure-Time Mixture Models for Analyzing Time to 
Response 
● Statistical Considerations in Multi-Regional Clinical Trials 
● Enrollment and Event Projection in Oncology Trials 
● Implementing the Continuous Reassessment Method 
(CRM) in a Phase I Oncology Trial 
● Scaled Average Bioequivalence: An Approach to Resolve 
A Difficult Program 
● Design of Non-inferiority Trials-Problems, Current 
Approaches and Applications of Inferiority Index 
● Methodological Considerations in Comparative 
Effectiveness Research 
● Estimation Issues for High Throughput Data 
● Multiple Testing in a Partitioning framework 
● Recent Development in Addressing Multiplicity Issues In 
Clinical Trials 
● Decomposition of a Composite Endpoint for Assessing 
Treatment Benefits for its Components 
1  23 
BASS XVII: Koch & Stocks, Nov. 10 
● Categorical Data Analysis Using SAS 
● Quantal Bioassay Analysis 
● The 2 x 2 Table 
● The Final Session: Recent Topics in Categorical Data 
Analysis 
● Biomarker Adaptive Threshold Design 
● Development and Validation of Predictive Classifiers 
using High Dimensional Data 
● Proportional Odds and Generalized Logits Models 
● Weighted Least Squares for Mean Scores 
● Sets of 2 x r and s x 2 Tables 
● Poisson Regression 













Clinical trials methodology (graduate course)  2  1 
Clinical trials methodology (graduate course) continued  2  2 
Clinical trials methodology 
●  Intro to methodology papers 
●  Analysis of Ratios and Decision Rules in Bioequivalence 
Studies 
●  Bioavailability and Bioequivalence of Pharmaceutical 
Formulations 
●  Design and Analysis of Pivotal Trials to Assess Efficacy of 
Drugs to Treat Panic 
● Tagamet: Repairing Ulcers Without Surgery (excerpt) 
●  Analysis of Ratios and Decision Rules in Bioequivalence 
Studies 
● Clinical Trials in the Prevention of NSAID Induced Gastric 
Ulceration 
● Biostatistical Aspects of the Development of H2-Receptor 
Antagonist Drugs to Treat Duodenal Ulcers 
● A Single Nocturnal Dose of Cimetidine in Active Duodenal 
Ulcer 
● Cimetidine Single-Dose Active Duodenal Ulcer Trial 
● Effects of Two Cimetidine Dosage Regimens on Serum 
Theophylline Levels 
● Efficacy of a Single Nocturnal Dose of Cimetidine in 
Active Duodenal Ulcer 
2  3 
Folder 4: Clinical trials methodology continued 
● Biostatistical Aspects of the Development of Anti-Anginal 
Drugs: a Phase II Trial Incorporating an Equiradial 
Hexagonal Design with RSM 
● The Importance of Numbers (of Patients) in Clinical Trials 
● The Pooling of Data from Multicentre Clinical Trials 
● Nonsequential Analysis of Time to Event Data 
● Additional Examples of Time-To-Event Analyses 
● Design Aspects of Cancer Clinical Trials 
● FDA Requirements for Approval of New Drugs 
● Guidelines for the Clinical Evaluation of Antineoplastic 
Drugs, February 1981 
2  4 
Clinical trials methodology (Grad course for MPH Biostat)  2  5 




● Statistical Principles for Clinical Trials 
● Guideline for Good Clinical Practice 
● Choice of Control Group and Related Issue in Clinical 
Trials 
● Principles for Clinical Evaluation of New Antihypertensive 
Drugs 
● FDA Organization Charts 
● ICH Press Reports, 1997-2000 
● User Fee Correspondence from the FDA, 1997 
● Federal Register, 1999 
Clinical trials & Biostatistics  2  7 
Biostatistical aspects of clinical research programs  2  8 
Cancer clinical investigation review committee, Apr. 1978 
● Bayesian Approach to Design of Clinical Trials 
2  9 
Clinical trials talk at Duke, 03/26/2008 
● Interesting Pharmaceutical Clinical Trial Applications 
2  10 
Interval-censoring in Biopharmaceutical clinical trials, 
07/14/2010 
● Interval-Censoring in Biomedical and Biopharmaceutical 
Clinical Trials Presentation 
● Interval-Censoring in Biomedical and Biopharmaceutical 
Clinical Trials Journal Article 
2  11 
Education of clinical trial statisticians 
● The Education of Clinical Trial Statisticians: Do we need to 
change with the time? Presentation 
● DIA program, 1991 
● Scott Evans Email, 2008 
● Scott Evans Email, 2007 
● Title page of the program for The Education of Clinical 
Trial Statisticians 
● Some Comments on the Biopharmaceutical Section and 
Statistics, 1989 
● The Future of the Education of Clinical Trial Statisticians: 
What Changes are Needed? 
● XXIVth International Biometric Conference sheet 
2  12 
Clinical trial protocol  2  13 
Workshop on clinical trials 
● Statistical Aspects of Clinical Drug Development 
2  14 
Clinical trial workshop S.K.& F.  2  15 
14 
● Smith Kline and French In House Biostatistical 
Educational Program; A Two Day Session on the Clinical 
Trials Workshop and Seminar Series; Presentation 1983 
Workshop on clinical trials, Dec. 8-9, 1983  2  16 
Introduction to S.K.& F. clinical trials 
● Papers and microfiche 
2  17 
RAPS 1992 
● Sample Size Considerations in Clinical Trials Premarket 
Approval, 1992 
2  18 
Clinical trial transparencies  2  19 
Multicenter trials  2  20 
Numbers of patients in clinical trials  2  21 
S.K.& F. protocol (transparencies)  2  22 








Number   
Folder 
Number  
Design Aspects of Cancer Clinical Trials 3 1 
Bioavailability & Bioequivalence 3 2 
Nonsequential Analysis of Time to Event Data 3 3 
Sequential Methods 3 4 
Sequential Methods continued 3 5 
Biostatistical Aspects of Clinical Drug Development 
● Includes microfiche 
3 6 
Statistics Issues Course handouts 




● Additional Examples of Time-To-Event Analyses 
Statistical Issues Course continued (Photocopied 
Transparencies) 
● Active Control Equivalence Studies 
● Dosing in the Elderly 
● The Pooling of Data from Multi-Centre Clinical Trials 
● Design, Monitoring, and Analysis Issue Relative to 
Adverse Events 
● Summarization, Analysis, and Monitoring of Adverse 
Experiences, REFERENCES/Chapter 2 
● Two Treatment Crossover Designs References/Chapter 3 
● Active Control Equivalence Studies 
REFERENCES/Chapter 4 
● Optimization in Clinical Trials and Combination Drug 
Development References/Chapter 5 
● Meta-Analyses in Ulcer Disease 
● An Evaluation of Triprolidine and Pseudoephedrine in the 
Treatment of Allergic Rhinitis 
● Summarization, Analysis, and Monitoring of Adverse 
Experiences, REFERENCES/Chapter 2 
3 8 
Graduate course in Biostatistics for Medical Personnel 
● Clinical Trials Methodology (name of Biostatistics course) 
3 9 
Canda Guidance Manual 2 nd Edition, October 1994 
● FDA Organization Charts 
● Canda Manual 
● FDA Organization Charts 
3 10 
The Assessment of Drug Safety, 05/10/1988 3 11 
Monitoring Adverse Experiences in Clinical Drug Development 3 12 
 






Institute for Professional Education, 1989-1990  4  1 
Courses: Drug Information Association, 1989 
● Correspondence 
4  2 




Courses: Statistical Aspects of Clinical Research Programs  4  4 
Short Course on Analysis of Cancer Clinical Trials 
● Nonsequential Analysis of Time to Event Data 
● Additional Examples of Time-To-Event Analyses 
● INCLUDES A Short Course on the Design of Cancer 
Clinical Trials 
● Design Aspects of Cancer Clinical Trials 
● Guidelines for the Clinical Evaluation of Antineoplastic 
Drugs 
4  5 
Short Course on Analysis of Cancer Clinical Trials continued 
● Design Aspects of Cancer Clinical Trials 
● Nonsequential Analysis of Time to Event Data 
● The Importance of Numbers (of Patients) in Cancer Clinical 
Trials 
4  6 
Guide for Biostatistical clinical trials methodology course 
● Course Overview 
● Biostatistical Aspects of the Development of Drugs to 
Treat Alzheimer’s Disease based upon ‘Enrichment 
Designs’ 
4  7 
Binder of an Overview of the Regulation of Pharmaceuticals 
presentation I 
4  Binder 
Binder of an Overview of the Process of Discovery, Basic 
Research, Clinical Development & Manufacturing in 
Pharmaceutical Development presentation II 
4  Binder 
Binder of Biostatistical Aspects of Clinical Drug Development 
presentation III 
4  Binder 
Binder of Bioavailability and Bioequivalence of Pharmaceutical 
Formulations presentation IV-a 
4  Binder 
Binder of Analysis of Ratios and Decision Rules in Bioequivalence 
Studies presentation IV-b 
4  Binder 
Binder of The Design and Analysis of Pivotal Clinical Trials to 
Assess the Efficacy of Drugs to Treat Panic Disorder presentation 
V 
4  Binder 
Binder of Clinical Trials in the Prevention of NSAID Induced Gastric 
Ulceration presentation VI 
4  Binder 
Binder of Biostatistical Aspects of the Development of H-2 




Binder of Biostatistical Aspects of the Development of 
Anti-Anginal Drugs: a Phase II Clinical Trial Incorporating an 
Equiradial Hexagonal Design with Response Surface 
Methodology presentation VIII 
4  Binder 
Binder of The Importance of Numbers (of Patients) in Cancer 
Clinical Trials presentation IX 
4  Binder 
Binder of Biostatistical Aspects of the Design of Cancer Clinical 
Trials presentation X 
4  Binder 
Binder of Biostatistical Aspects of the Analysis and Interpretation 
of Cancer Clinical Trials presentation XI 
4  Binder 
Binder of Monitoring Adverse Experiences in Clinical Drug 
Development presentation XII 
4  Binder 
Binder of The Pooling of Data from Multicentre Clinical Trials 
presentation XIII 
4  Binder 
Binder of Interim Analyses: p-Value and Power Computations in 
Multiple Look Trials presentation XIV 
4  Binder 
Binder of Biostatistical Aspects of Development of Drugs to Treat 
Alzheimer’s Disease Based Upon Enrichment Designs 
presentation XV 
4  Binder 
J & J Course, 1990 (Johnson & Johnson)  4  8 
Lectures (Oncology studies) 
● Statistical Input into the Design, Analysis and Interpretation 
of Oncology Studies 
● Nonsequential Analysis of Time to Event Data 
● Additional Examples of Time-To-Event Analyses 
● Non-sequential Analysis of Time To Event Data 
● Survival Analysis Articles x5 
● Analysis of Survival Data Articles x4 
● Multivariate Survival Analysis Articles and Articles on 
Competing Risks 
4  9 
Lectures (Oncology studies) continued 
● Design Aspects of Cancer Clincal Trials 
● Connection Between the Mantel-Haenszel and Cox 
Procedures for the Two Sample Case, 1979 




Clinical trials & Biostatistics lecture 
● Thank You Card 
● Clinical Trials and Biostatistics presentation 
● Real Problems Call for Statistical Solutions presentation 
4  11 
Biostatistical aspects of development of drugs lecture 
● Biostatistical Aspects of Development of Drugs to Treat 
Alzheimer’s Disease Based Upon Enrichment Designs 
4  12 
Prevention of NSAID lecture 
● Clinical Trials in the Prevention of NSAID Induced Gastric 
Ulceration 
4  13 










Matched pair design in controlling confounding factors in 
spontaneous duodenal ulcer relapse, 1987 
5  1 
Study design for the assessment of misoprostol in the 
treatment & prophylaxis of NSAID induced peptic ulcer, 1987 
5  2 
A blind endoscopic comparative study of misoprostol vs. 
sucralfate & placebo in the prevention of aspirin-induced 
gastric & duodenal ulceration, 1987 
5  3 
A blind endoscopic comparative study of misoprostol vs. 
sucralfate & placebo in the prevention of aspirin-induced 
gastric &  duodenal ulceration (continued), 1987 
5  4 
Duodenal ulcer- what comes after healing? 1987  5  5 
Prevention of gastric ulceration upon reinstituting NSAID 
therapy in Osteo-Arthritic patients, 1987-1988 
● Meta-analysis of Duodenal Ulcer Relapses Using Actual 
Patient Data: A Comparison of the Effect of Acute 
Treatment with Cimetidine, Misoprostol and Placebo 
5  6 
NEJM manuscript, 1985-1986 
● Acid Suppression – How Much and When for Acute 
Duodenal Ulcer Healing? 
● Nocturnal Cimetidine Therapy to Treat Duodenal Ulcers; 
5  7 
19 
a Dose Response Study 
● One Article by John Romankiewicz 
● Effectiveness of Cimetidine in Doses of 400 mg, 800 mg 
and 1600 mg Given at Bedtime for the Acute Treatment 
of Duodenal Ulcers 
Maxzide clinical manuscript 11/1987 
● Comparative Bioavailability of Two Pharmaceutical 
Formulations Containing 
● Hydrochlorothiazide and Triamterene 
● Influence of Tablet Dissolution on Furosemide 
Bioavailability: A Bioequivalence Study by McNamara, 
Foster, Digenis, Patel, Craig, Welling, Rapaka, Prasad, 
and Shah 
5  8 
A double-blind crossover comparison of equal daily doses, 
1987 
● Two Abstracts for the American College of Cardiology 
● Comparison of Equivalent Oral Doses of Verapamil and 
Diltiazem in Patients with Mild to Moderate Hypertension 
● A Double Blind Crossover Comparison of Equivalent 
Doses of Oral Verapamil and Diltiazem in Patients with 
Mild to Moderate Hypertension 
5  9 
Betaxalol Vs. Atenolol serum level Fluetuatron study, 
1987-1988 




● The Steady State Plasma Profile of Betaxolol as 
Compared to Atenolol 
5  10 
Bioequivalency of controlled release & sustained release 
formulations of verapamil HCL following multiple dosing in 
normal healthy male volunteers, 1987 
● Comparative Steady State Bioavailability of 
Conventional and Controlled- Release Formulations of 
Albuterol by Powell, Weisberger, Dowdy, Gural, 
Symchowicz, and Patrick (1987) 
5  11 
Estimation of survival parameters  5  12 
Some results in the estimation of survival parameters  5  13 
A brief review of correlation, 10/1976  5  14 
Statistical report of Searle protocol, 1988  5  15 
20 
● Abstract to the American College of Cardiology: 
Variability of Left Ventricular Mass Measurements by 
Ultrafast Computed Tomography 
● Abstract to the American College of Cardiology: 
Measurement of Myocardial Blood Flow After 
Transdermal Nitroglycerin by Ultrafast Computed 
Tomography 
Sequential analysis book visuals, 04/1986 
● P-Value and Power Computation in Multiple Look Trials 
transparency 
● Mathematical Statistics by Thomas Ferguson 
● Sequential Tests of Hypotheses for the Reliability of a 




● Effect of Antilyphocyte-Globulin Potency on Survival of 
Cadaver Renal Transplants, 1977 
● Performing a Survival Analysis Instead of an Endpoint 
Analysis 
● The Design of a Sequential Clinical Trial for the 
Comparison of Two Lung Cancer Treatments by Jones, 
Newman, and Whitehead (1982) 
● Sequential Analysis of Survival Data in Clinical Trials by 
Gordon Lan (1984; handwritten) 
● Discrete Sequential Boundaries for Clinical Trials by Lan 
and DeMets (1983) 
● More Flexible Sequential and Non-Sequential Designs in 
Long-Term Clinical Trials by Lan, DeMets, and Halperin 
● Temple University program for Gordon Lan’s Sequential 
Analysis of Survival Data in Clinical Trials 
● Exact Confidence Intervals Following a Group 
Sequential Test by Tsiatis, Rosner, and Mehta (1983) 
5  16 
Sequential analysis book visuals continued 
● Notes 
● A Generalized Wilcoxon Test for Comparing Arbitrarily 
Singly-Censored Samples by Edmund Gehan (1965) 
● ‘Lecture 6’ Notes 
● Evaluation of Survival Data and Two New Rank Order 
Statistics Arising in its Consideration by Nathaniel Mantel 
(1966) 
● Evaluation of Response-Time Data Involving Transient 
States: An Illustration Using Heart-Transplant Data by 
Mantel and Byar (1974) 
● The Effect of 6-Mercaptopurine on the Duration of 
5  17 
21 
Steroid-induced Remissions in Acute Leukemia: A Model 
for Evaluation of Other Potentially Useful Therapy by 
Freireich, Gehan, Frei, Schroeder, Wolman, et al. 
● Notes 
Exposure analysis of Dichotomous response measures in 
long-term studies, 1993 
5  18 
Summary of BRCI analyses of ADAS-Cog & CGIC from 
protocals CI-970-01, 04, and 06; 11/1992 
5  19 
Ulcer papers, 80’s & one 2011 
● Meta-Analyses in Ulcer Disease 
● Effects of Two Cimetidine Dosage Regimens on Serum 
Theophylline Levels by Seaman, Randolph, Peace, 
Frank, Dickson, Putterman, and Young (1985) 
● The Treatment of Gastric Ulcer with Antisecretory Drugs: 
Relationship of Pharmacological Effect to Healing Rates 
by Howden, Jones, Peace, Burget, and Hunt (1988) 
● Case Study in Optimal Dosing in Duodenal Ulcer 
● Info on the ‘Peptic Ulcer Disease’ book 
● Early Termination of Two Trials of Misoprostol in the 
Prevention of NSAID- Induced Gastric Ulceration (1992) 
● Efficacy of a Single Nocturnal Dose of Cimetidine in 
Active Duodenal Ulcer by Valenzuela, Dickson, Dixon, 
Peace, Putterman, and Young (1985) 
● A Single Nocturnal Dose of Cimetidine in Active 
Duodenal Ulcer by Peace, Dickson, Dixon, Putterman, 
and Young (1985) 
● Cimetidine Single-Dose Active Duodenal Ulcer Trial by 
Dickson, Dixon, Peace, Putterman, and Young (1985) 
● Determining the Optimal Dosage Regimen for 
H2-Receptor Antagonist Therapy – a dose validation 
approach by Young, Frank, Dickson, Peace, Braverman, 
and Mounce (1989) 




A brief review of correlation, 1/77  5  21 
Time to event data, 1988-2006  5  22 
Prediction probabilities in stability studies, 11/83  5  23 




Appendix 9. Methodology for the computation of partial areas 
under the Nar time curves 
5  25 
Size & power assessments of tests of hypotheses on survival 
parameters, 1978-1980 
5  26 
Second revision of size & power assessments of tests of 
hypotheses on survival parameters, 1977-1978 
● Size and Power Assessments of Tests of Hypotheses on 
Survival Parameters by Peace and Flora (1977 & 1978 
printed copy) 
5  27 










Size & power assessments of tests of hypotheses on survival 
parameters 
6  1 
Exposure analysis of Dichotomous data 
● Exposure Analysis of Dichotomous Data draft and 
transparencies 
● On the Analysis of a Combination of Two Primary Efficacy 
Measures 
6  2 
Estimating the probability of the superiority of one treatment to 
another, 8/9/85 
6  3 
A brief review of correlation, 11/19/76 
● Includes transparencies 
6  4 
Connection between the Mantel-Haenszel & Cox procedures for 
the two sample case, 12/17/79 
6  5 
Some results in the estimation of survival parameters, 4/30/76  6  6 
Proceedings of the National Academy of Sciences (PNAS) 
miscellaneous, 1992 
● Methodological Aspects of a Population Pharmacodynamic 
Model for Cognitive Effects in Alzheimer Patients Treated 
with Tacrine by Holford and Peace (1992) 
● Results and Validation of a Population Pharmacodynamic 
Model for Cognitive Effects in Alzheimer Patients Treated 
6  7 
23 
with Tacrine by Holford and Peace (1992) 
● A Double-Blind, Placebo-Controlled Multicenter Study of 
Tacrine for Alzheimer’s Disease by Davis, Thal, Gamzu, 
Davis, Woolson, Gracon, et al. 
● Controlled Trial of Tacrine by Farlow et al 
Proceedings of the National Academy of Sciences (PNAS) 
miscellaneous continued, 1992 
● A Controlled Trial of Tacrine in Alzheimer’s Disease by 
Farlow, Gracon, Hershey, Lewis, Sadowsky, and 
Dolan-Ureno (1992) 
● Methodological Aspects of a Population Pharmacodynamic 
Model for Cognitive Effects in Alzheimer Patients Treated 
with Tacrine by Holford and Peace (1992) 
● Results and Validation of a Population Pharmacodynamic 
Model for Cognitive Effects in Alzheimer Patients Treated 
with Tacrine by Holford and Peace (1992) 
6  8 
Final Proceedings of the National Academy of Sciences (PNAS) 
manuscripts, 1992 
● Methodological Aspects of a Population Pharmacodynamic 
Model for Cognitive Effects in Alzheimer Patients Treated 
with Tacrine by Holford and Peace  
○ Draft of this article too 
● Results and Validation of a Population Pharmacodynamic 
Model for Cognitive Effects in Alzheimer Patients Treated 
with Tacrine by Holford and Peace 
○ Draft of this article too 
6  9 
Proceedings of the National Academy of Sciences (PNAS) 
manuscripts: reviewer/revisions, 1992 
● Tacrine in Alzheimer’s Disease: A Population 
Pharmacodynamic Model for Cognitive Effects parts I and II 
○ Includes a set of drafts 
6  10 
Proceedings of the National Academy of Sciences (PNAS) 
manuscripts: reviewer/revisions continued, 6/29/92 
● Tacrine in Alzheimer’s Disease: A Population 
Pharmacodynamic Model for Cognitive Effects parts I and II 
Drafts 
6  11 
Determining type I & type II errors in multiple trials, 1980 
● Size of the Type I Error at which to Conduct an Interim 
Analysis in Order that the Results of the Interim and Final 
Analyses are Significant, 1980 
6  12 
Letters to the editor  6  13 
24 
Letters to the editor: NEJM (New England Journal of Medicine), 
1984 
6  14 
Letters to the editor: Lancet, 11/10/84  6  15 
Letters to the editor: journal of chronic diseases, 1987  6  16 
JBS subgroup paper, 2009-2010 
● Analysis of Subgroup Data of Clinical Trials by Tsai and 
Peace 
6  17 
Duodenal ulcers paper, 1/2010 
● Clinically Optimal Dosing in the Treatment of Duodenal 
Ulcers: A Case Study of a Phase III SNDA Clinical Program 
6  18 
DIA sample size, 11/19/91 
● Sample Size Considerations in Clinical Trials Premarket 
Approval 
6  19 
Manuscripts with Kao-Tai Tsai, 2005 
● Multivariate Dose Response Test by Kao-Tai Tsai and Karl 
Peace 
6  20 
Multivariate dose response JMS; Peace & Tsai, 2007 
● o Multivariate Dose Response Test by Kao-Tai Tsai and Karl 
PeaceIncludes Drafts and a powerpoint 
● Correspondence 
● Nonparametric Two-Sample Comparisons of Changes on 
Ordinal Responses by Bajorski and Petkau (1999) 
6  21 
A brief introduction to survival curve estimation, 10/31/75  6  22 
Some results in the estimation of survival parameters, 4/30/76  6  23 
Estimation & tests of hypotheses on survival parameters, 5/17/79  6  24 
A brief review of correlation  6  25 
Bivariate plot paper JBS, 2008-2009 
● Bivariate or Composite Plots of Endpoints by Peace and 
Tsai 
● Bivariate or Composite Plots of Primary Endpoints by Peace 
and Tsai 
6  27 
Multivariate dose response test, 2008-2009 
● Multivariate Dose Response Test by Tsai and Peace Various 
versions 
● Article comments from reviewers 
● The Fibroblast Growth Factor Receptor Gene Arg 388 Allele 
6  28 
25 
is not Associated with Early Lymph Node Metastasis of 
Breast Cancer by Becker, Nieters, and Chang-Claude (2003) 
● Analysis of Dose-Response Relationships on Complex 
Survey Data by Judkins, Zador, and Nadimpalli (2002) 
The use of response surface methodology in the development of 
antianginal drugs (handout), 5/29/86 
6  29 
Lopid manuscripts: HHS I: exposure analysis, 11/23/91 
● Statistical Analysis Methods for Providing Inferences 
between Primary Response Measures and Exposure to 
Study Medication in the Helsinki Heart Study: Double Blind 
and Open Label Periods by Peace and Haber (1991) 
6  30 
Lopid manuscripts: HHS II: exposure analysis, 1991-1992 
● Exposure Analysis of Dichotomous Response Measures in 
Long Term Studies, 1992 
● Statistical Analysis Methods for Providing Inferences 
Between Primary Response Measures and Exposure to 
Study Medication in Long Term Studies 
● Drafts, Revisions, and Reviews 
● Compliance as an Explanatory Variable in Clinical Trials by 
Efron and Feldman (1991) 
● Exposure Analysis of Dichotomous Response Measures in 
Long-Term Studies by Peace and Carter Jr. (1992) 
6  31 
Lopid manuscripts: Zweig & Urquhart, 92-93 
● Correspondences 
● Xerox Telecopied Compliance as an Explanatory Variable in 
Clinical Trials by Efron and Feldman (1991) 
● Medication Compliance and Serum Lipid Changes in the 
Helsinki Heart Study by Maenpaa, Heinonen, and Manninen 
(1991) 
6  32 
Life time learning publications, 1/10/83  6  33 
Miscellaneous papers from Biopharmaceutical research 
consultants, INC. 
● Biostatistical Aspects of the Development of Anti-anginal 
Drugs: a Phase II Trial Incorporating an Equiradial 
Hexagonal Design with RSM notes 
● Design and Analysis of Pivotal Trials to Assess Efficacy of 
Drugs to Treat Panic notes 
● Biostatistical Aspects of the Development of Drugs to Treat 
Alzheimer’s Disease based upon ‘Enrichment Designs’ 




Miscellaneous papers from Biopharmaceutical research 
consultants, INC. continued 
● Monitoring Adverse Experiences in Clinical Drug 
Development 
● Bioavailability and Bioequivalence of Pharmaceutical 
Formulations 
● Analysis of Ratios and Decision Rules in Bioequivalence 
Studies 
● Biostatistical Aspects of the Development of H2-Receptor 
Antagonist Drugs to Treat Duodenal Ulcers 
6  35 
SJS (Steven Johnson Syndrom) research, 2004 
● (Re)Assessing the Co-Administration of Steroids and 
Antibiotics in the Management of Patients with Metastatic 
Brain Cancer research proposal 
● Correspondence 
● Notes 
● Intention-to-Treat Analysis and Accounting for Missing Data 
in Orthopaedic Randomized Clinical Trials by Herman, 
Botser, Tenenbaum, and Chechick (2010) 
6  36 
Drug information journal: articles, 87 & 93 
● Design, Monitoring, and Analysis Issues Relative to Adverse 
Events, 1987 
● Discussion for Interim Analysis and Sample Size 
Reestimation, 1993 
6  37 
Analysis of efficacy data on IBS patients, 6/9/81 
● Analysis of Efficacy Data on IBS Patients, in AHR Study 
4523/03, Who Presented at Entry With Both Day Pain and 
Night Pain; Patients Who Did Not Complete Study Are 
Carried Through With the Rating at Time of Dropout 
Assigned to Post-Dropout Visits. Supplement 2 to 
“Statistical Report of the Multi-Investigator Study of 
Donnatal, Belladonna Alkaloids, Phenobarbital and Placebo, 










To The Editor: Giles Robertson, 1975 
● Math notes 




● To the Editor 
Chapter 3: Section 1-3 deleted 
● 3.1.1.1.2 : The Weibull Density 
7  2 
Note concerning Fishers Method for Combining P-values 
● Notes 
7  3 
Letter about Journals 10/1/82 
● Notes 
7  4 
Analysis & interpretation of log transformed DATA 8/15/85 
● On The Analysis and Interpretation of log Transformed 
DATA 
● Background 








● The Teacher’s Corner 
● Designs for Estimating Variance Components 
● Introduction 
● Variances of Estimated Variance Components for a Three 
Stage Nested Classification 
● Optimal Designs for Estimating Parameters for a Three 
Stage Nested Classification 
● Some Aspects of the Simultaneous Estimation of Variance 
Components For a Three Stage Nested Classification 
7  6 
Goodness of Fit Test for Survival Models 10/3/79 
● Goodness of Fit Test For Failure Time Models utilizing 
covariates 
● Goodness of Fit Test For Model 
● Comparing Observed Life Table Data with a Known Survival 
Curve in the Presence of Random Censorship 
● Math notes 
● Letter from Karl E. Peace to Dr. Carol Redmond 
7  7 
 GCM analysis of Quantal data, 11/8/85  7  8 
Folder 9: Endpoint Analysis of DATA from trial of cyclical Disease 





Analysis of F & Z data, Freireich data & T.P. data, 2/3/76  7  10 
Analysis of F & Z data, Freireich data & T.P. data continued, 2/3/76  7  11 
Yvonne efficiency article 




Dose response problem, 10/15/91 
● Medical College of Virginia 
7  14 
Iterative solutions of F & Z normal equations, 12/65 
● Program For The Iterative Solution Of The Normal 
Equations of Feigl and Zelen 
● Estimation of Exponential Survival Probabilities with 
Concomitant Information: Feigl and Zelen 
7  15 
Survival curve anthology idea 
● An Anthology of Survival Curve Estimation 
● Chapter 3: The Actuarial Method 
7  16 
Contrasting linear additive model with YIJ  7  17 
Parameter estimation LDIO, LDSO, etc, 1/9/85 
● Pinhole Tester (Densok) 
7  18 
Nature of the Difference Between The Mantel-Haenszel  7  19 
Parameter Estimating LD10,LD50, ETC 1/9/85 
● Northwest Orient 
7  20 
Europa distribution related book  7  21 
Guide to decision making involving human experimentation (C.K. 
Himmelsback), 12/30/76 
● Letter to Chif 
● Guide to Decision Making in Human Experimentation 
7  22 
Consulting project: Giles, 9/10/75 
● The Hypocalcemia of Acute Pancreatitis 
● Letter to the Editor 
● Letter to Giles from Karl 
● Final Letter to the Editor From Karl 
7  23 
Study proposals for generics, 1982  7  24 
29 
● Study Proposites For Generies Existing Indications 
● Clinical Research Protocol 
Design, Analysis & Interpretation of Oncology Trials 1/9/84 
1. Note concerning Fishers method for combining P-values 
2. Letter about journals, 10/1/82 
3. Analysis & interpretation of log transformed data, 8/15/85 
4. Hale’s problem, 2/05/79 
5. Goodness of fit test for survival models, 10/3/79 
7. Endpoint analysis of data from trial of cyclical disease 
8. Analysis of F & Z data, Freireich data & T.P. data, 2/3/76 
9. Analysis of F & Z data, Freireich data & T.P. data continued, 
2/3/76 
10. Yvonne efficiency article 
11. RPB 
12. Dose response problem, 10/15/91 
13. Iterative solutions of F & Z normal equations, 12/65 
14. Survival curve anthology idea 
15. Contrasting linear additive model with YIJ 
16. Pinhole testing problem, 6/6/79 
17. On the nature of the difference between the Mantle-Haenszel, 
PETO & PETO tests 
18. Parameter estimation LDIO, LDSO, etc, 1/9/85 
19. Europa distribution related book 
20. Guide to decision making involving human experimentation 
(C.K. Himmelsback), 12/30/76 
21. Consulting project: Giles, 9/10/75 
22. Study proposals for generics, 1982 
23. Design, Analysis & Interpretation of Oncology trials, 1/9/84 
7  25 
Mathematical Physiology ( Finite Markov chains & stochastic 
processes with applications), 1976 
7  26 
A brief introduction to survival curve estimation, 10/31/1975  7  27 
Marginal likelihoods based on Cox’s regression & life model, 1972  7  28 










One-sided or Two-sided? 8/16/1988  8  1 
30 
One-sided or Two-sided? Continued, 8/16/1988  8  2 
Some thoughts on One-tailed tests (letter to the editor), 1988  8  3 
Technometrics letter to the editor, 10/1/1980  8  4 
The treatment of gastric ulcer with antisecretory drugs, 10/86  8  5 
What hypothesis is being addressed in the analysis of change 
scores? 6/10/80 
8  6 
A characterization of the effect of varying sample sizes, subject to a 
fixed total, on detecting a difference in two means, 1/7/80 
8  7 
Tests of hypothesis in two by two tables, 1980  8  8 
Connection between the Mantel-Haenszel & Cox procedures for 
the two sample case, 3/14/80 
8  9 
The Statistician Article: A two-treatment, two-period, crossover 
design permitting assessment of direct & carry-over effects, 
8/23/83 
8  10 
P-value & power computations in multiple look trials, 1987  8  11 
P-value & power computations in multiple look trials, 4/3/86  8  12 
P-value & power computations in multiple look trials continued, 
4/3/86 
8  13 
Charts P-value & power computations, 4/3/86  8  14 
Design, analysis & interpretation of Oncology trials, 12/14/84  8  15 
Copies of articles by K.E.P., 1988-2006  8  16 
Copies of articles by K.E.P. continued, 1988-2006  8  17 
Copies of articles by K.E.P. continued, 1988-2006  8  18 
Statistics handouts by K.E.P.  8  19 
Statistics handouts by K.E.P. continued  8  20 
PSA papers ( Panic trials 06, Survival analysis instead of an end 
point analysis for antibiotic data 06, Statistical analysis methods for 
providing inferences between primary response measures 06) 
8  21 
ASA articles, 1989 & 2008  8  22 
31 
Copies of articles, 1979-2007  8  23 








Berkeley Wellness Letters  9  1 








Loose Items  10  1 
Car calendars- pictures from the private collection of Dr. Karl E. 
Peace 
● 1. (white binder) 




● Health Systems Plan 1979-1980 (items not in folder) 
● Speaker and Brochure Information- Optimizing Dose and 
Exposure-Response Studies to Reduce Drug Development 
Time and Expense 
● The Summer Meeting in Eugene 
10  3 
1986 Munice Meetings 5/29/86 and The 1986 Midwest 
Biopharmaceutical Workshop 
10  4 
“Issues Concerning the Dose Comparison Trail” PMA 1983 Annual 
Meeting 
10  5 
APHA Meeting (7/25-27, 2010)  10  6 
APHA Meeting – December 11, 2010  10  7 
Inter-Sectional Council (ISC) Agenda –APHA (transparent folder)  10  8 
APHA- Philly 11/10-11/12 2009 \  10  9 
32 
(loose item) 
● The History of the Biopharmaceutical Section of the 
American Statistical Association (ASA), 1966-1988 
Column for PSA Newsletter  10  10 
PSA Column 1: Q or A? Importance of the Research Questions 
relative to Analyses 
10  11 
Letter to the Editor 
● Is it better to have many small trials or few large trials? 
● Observations 
● Some Thoughts on Confirmatory Evidence (CE) to Support a 
Single Clinical Trial as a Basis for Drug Approval 
● Clinical Development Program 
● On the Need for Placebo in Combination Drug Development 
● Combination Drugs 
● Placebo is needed to Establish Efficacy in Combination Drug 
Development 
● Response 
● letter from Karl E. Peace to Dr. Alvan R. Reinstein Jan 22, 
1990 
● letter to the Editor 
● letter from Karl E. Peace to Dr. Alvan R. Reinstein Jan 17, 
1990 
● letter from Alvan R. Reinstein and Walter O. Spitzer to Karl E. 
Peace 
● handwritten pages – stapled 
● The Impact of Investigator Heterogeneity in clinical Trials on 
Detecting Treatment Differences 
● Some Comments on the Biopharmaceutical Section and 
Statistics 
10  12 
PSA Column 2: Validity of Statistical Inferences from Medical 
Experiments (PSA Newsletter) 
10  13 
PSA Column 3: “Fixed Combination…”  10  14 
PSA Column 4: “Bio statistical Aspects of NSAID and Gastric Ulcers”  10  15 
Manuscripts for PAS 
● email correspondence between Joselito C. Magadia and 
Karl E. Peace 
● mathematical update and clarification 
● email correspondence between Jose Ramon G. Albert and 
Karl Peace 
10  16 
Talk to PSA  10  17 
33 
● receipts including hotel bill 
● email correspondence between William I. Griffis and Karl E. 
Peace 
● email correspondence between Dalsay Maligalig and Karl E. 
Peace 
● travel agent invoice 
● email correspondence between Robert Vogel and Karl E. 
Peace 
● email correspondence between Jose Ramon G. Albert and 
Dalisay 
Combination GSU and UP Los Banos 
● email correspondence between Nancy Shumaker and Karl 
E. Peace 
● email correspondence between Dr. Carter and Karl E. Peace 
● background 
  18 
Related to PSA Newsletter  10  19 
PS column: statistics in medical science  10  20 
PS Column: Statistics in medical science  10  21 
ASA Summer Meeting – 1994  10  22 




Analysis of Survival Data Course (browned accordion folder)  10  25 
Unlabeled 
● Assessment of Drug Safety 
● PMA Education and Research Institute (PERI) Third Annual 
Training Course for New Clinical Statisticians March 11 -13, 
1990 
● The FDA and the IND/NDA Statistical Review Process 
● Bioavailability/ Bioequivalence Trials Design and Evaluation 
● Protocol Development –A Statistician’s Point of View 
● Planning of Clinical Studies 
● Acceleration of the Drug Approval Process 
● Investigational New Drug, Antibiotic, and Biological Drug 
Product Regulations: Procedures for Drugs Intended to Treat 
Life- Threatening and Severely –Debilitating Illnesses 





● General Linear Models Procedure 
Statistical Services Seminar 
(loose items) 
● Pharmacometrics Impact on FDA Decisions and 
Recommendations: Past, Present, and Future 
10  27 
Unlabeled 
● letter from Drug Information Association 
● two sheets of slides – statistical Considerations in the design 
and Analysis of LOPID-MR Placebo –Controlled Study 
● (loose items) 
● regulatory affairs 
● Clinical Studies: how to Successfully Resolve Clinical 
Problems to Achieve FDA Approval 
10  28 



















-Statistical Analysis Methods for Providing Inferences between 
Primary Response Measures and Exposure to Study Medication 
● A Survival Analysis Instead of an Endpoint Analysis for 
Antibiotic Data 
● Statistical Computing and Graphics – Word from Computing 
Section Chair 
● Statistical Methods for a Three-Period Crossover Design in 
Which High Dose Cannot Be Used First 
● Statistical Input into the Design, Analysis and Interpretation of 
Clinical Trails 
● Assessing the Validity of Statistical Inferences in Public 
12  1 
35 
Health Research: an Evidence-Based, ‘Best Practices’ 
Approach 
● Statistical Methods for a Three-Period Crossover Design in 
Which High Dose Cannot Be Used First 
● Statistics in Medical Science-Importance of Research 
Question Relative to Analyses 
Stats (cont’d) 
● Some Comments on the Biopharmaceutical Section and 
Statistics 
● Some Thoughts on the Development of Combination Drugs 
● The history of the Biopharmaceutical Section of the 
American Statistical Association (ASA), 1966-1988 
● Introduction of the Bass XVIII Keynote Speaker Dr. Marvin 
Zelen 
● Making Informed Consent More Ethical 
● A Call to Action 
● Safety of Drugs, indeed, a Lifecycle Exercise 
● An Evaluation of Triprolidine and Pseudoephedrine in the 
Treatment of Allergic Rhinitis 
● Discussion for Interim Analysis and Sample Size Reestimation 
● Statistical Tests for Indirectly Standardized Rates 
● Appendix 1 Statistical Test 
● (Loose items) 
● Resampling Stats- Probability and Statistics a Radically 
Different Way User Guide IBM Version 3.0 (w/2 floppy disks) 
● Journal of Biopharmaceutical Statistics 
● Purpose of Experimentation or Observation (transparent 
slides) 
● Resampling Stats – Probability and Statistics a Radically 
Different Way Ibm Version 2.0 (in blue folder) 
● Biotechnology and the Biostatician 
● Keynote Address, Preliminary Comments: by Karl Peace, 
BASS Chair, GCC Distinguished Cancer Scholar, Senior 
Research Scientist, JPHCPH, GSU. 
● Summary of Linear Models Analyses of ADAS-COG and CGIC 
Scores from Three Placebo Controlled, Enrichment Studies 
of Tacrine 
● Discussion: Linear Models and Population PK/PD Models 
● Statistical Issues in the Pharmaceutical Industry: Design, 
Analysis and Interpretation Issues in Clinical Trails 
● The Effect of Tacrine on Alzheimer’s Disease 
● Analysis of Menstrual Data from Contraceptive Trials 
● Comparing Treatment Groups on the Basis of Slopes, 
Areas-Under-The-Curve, and Other Summary Measures 
● Maximum Likelihood Assessment of Clinical Trials based on 
an Ordered Categorical Response Variable 
12  2 
36 
● Reducing the Cost of Clinical Trials 
● Statistical Issues in the Pharmaceutical Industry: Design, 
analysis and Interpretation Issues in Clinical Trials 
Wyeth Ayerst 
● Hotel receipt 
● Wyeth-Ayerst Biostatistical Seminar 
● Handwritten note on Biopharmaceutical Research 
Consultants Inc. letterhead 
● Letter from Richard Entsuah, Ph.D to Karl Peace about 
Wyeth-Ayerst seminar 
● Some Statistical Issues in Pharmaceutical Applications 
● Memo to Dr. Richard Entsuah from Karl Peace – Abstract of 
Presentation 
● Handwritten note 
● Note from Dr. Richard Entsuah from Karl Peace 
12  3 
Barnett Educational Services: Drug Development 
● Applying FDA’s Critical Path Initiative to Oncology Drug 
Development 
● Drug Development: Changing the Paradigm outline 
● Speaker and Brochure Information- Drug Development: the 
Changing Paradigm 
● Karl E. Peace, Ph. D. Biographical Sketch 
● Sample Size Considerations in Clinical Trials Pre-Market 
Approved. 
12  4 





● Comparisions of Improvement vs. No Improvement for 
ADAS-COG, CGIC, and combined 
● Summary of Dose Response Analyses ADAS-COG at End of 
DB Treatment 
● Summary of Life Table Analyses of Time to First Clinical 
Response 
● Summary of Linear Model Analyses of ADAS-COG and CIBI 
Scores from Parallel, Placebo-Controlled Phases of Protocol 
CI-970-61 
● Summary of Linear Models Analyses of ADAS-COG and CGIC 
Scores from Three Placebo Controlled, Enrichment Studies 
of Tacrine 
● Clinical Pharmacology 




● Comparisons of Improvement vs. No Improvement for 
ADAS-COG (4 or More Point Reduction over Baseline) 
Protocols CI-970-01, -04, and -06 
● Life Table Analysis of Time to First Clinical Response 
Protocol CI-970-26 
● Experimental Design 
Carl Peck’s Oncology  12  7 
Georgetown University Medical School Center for Drug 
Development Science 
● handwritten notes on Georgetown letterhead 
● Carl Peck’s Oncology papers 
● email from Karl Peace to Carl Peck on Intrinsic Efficacy 
● email from Karl Peace to Carl Peck on combination Drug 
Development 
● Clinical Development of Oncologic Agents: Challenging the 
Tradition 
● Speaker Biographies 
● Clinical Development of Oncologic Agents: challenging the 
Tradition 
12  8 
Presentation at Princeton-Trenton chapter 
(loose items) 
● handwritten notes on Marriott Hotels and Resorts letterhead 
● Welcome to “Dose Response Clinical Trials” November 15-16, 
2004 
● Abstract From: American College of Gastroenterology 
● list of names 
● email from Joe Mason to Karl Peace about Barnett 




● not in folder- Dose response papers 
● not in folder 
● PMA Education and Research Institute (Peri) Training Course 
in Non- Clinical Statistics January 9-11, 1991 
12  10 









1986 Session on Draft Guideline  13  1 
Chicago Session on Content and Format of the Application 
● Research/Meetings –ASA Chicago Session 
13  2 
1986 Annual Joint Meeting, Chicago August 17-21 
● Empty 
13  3 
1986 Joint Meeting, Continuing Ed Subcommittee Meeting 
● ASA-Annual Joint Meetings 
13  4 
Executive Committee Meeting-1986 Joint Meeting 
● ASA-Annual Joint Meeting 
13  5 
1986 Joint Meeting, Session on the Clinical Guidelines 
● ASA-Annual Joint Meetings 
13  6 
DIA BA/BE Workshop/ 1991 August  13  7 
Time to Event ADTE Methods  13  8 
Design and Analysis of Bioavailability Studies 11/16/83  13  9 
Design and Analysis of Bioavailability Studies 11/16/83  13  10 
Safety Data Book Chapter  13  11 
PMA Med Section Training Seminar 
● Pharmaceutical Manufacturers 
13  12 




ENAR-3/18/86 Combination Drug Trials  13  15 
1986 Spring ENAR Meetings, Atlanta 
● Empty 
13  16 
1987 Spring ENAR Meetings  13  17 
Unlabeled 
● Continuous form stationary 
13  18 










● Handwritten note on Courtyard Marriott Stationary 
● Flash drive –Jiann-Ping Hsu College of Public Health 
● The Promise of Berkley Spring 2010 
● Punch cards 




● Paid in Full: Baker county Native Releases New Book of 
Memoirs 
● Ga Southern Scholar Receives Award from Philippine 
Statistical Association 
● Drug information Journal Author Guidelines AIMS and SCOPE 
● Journal of Epidemiology and Community Health –printout 
● Statistical Methods in Medical Research 
● Instructions for Authors “What AJPH authors Should Know” 
● Submission Guidelines for ICSA Bulletin 
● Protecting the Health of the Public – Institute of Medicine 
Recommendations on Drug Safety 
● Applied Clinical Trials 
● Email about Regulatory Affairs in Drug and Device 
Development – Gall for Manuscripts 
● Renowned Scholar and Pharmaceutical Researcher Endows 
chair in Biostatistics at UC Berkeley 
● Bioinformatics Internet Sites 
● Proteinuria in Gold-Treated Rheumatoid Arthritis 
● Safety of Drugs Is Indeed a Life Cycle Exercise 
● The Role of Vasopressin in Maternal Separation-Induced 
Short- Term Consequences and Adult Depressive Profile 
● Southeast (Waycross) Public Health District Perinatal and 
Premature Mortality Measures By Census Tract With County 
Commission Districts, 1998-2002 
● Baseline Cumulative Hazards Graphs 
● The Ten Commandments of Good Health-book 
● The Claxton Enterprise 
● Regents Launch Public Health Initiative To meet Increased 
Demand 
● BookFinder4u.com page- Design and Analysis of Clinical 
Trials with Time-to-Event Endpoints (Chapman & Hall/ Crc 
Biostatistics Series) 
14  1 
Citations of K.E. Peace papers  14  2 
40 
(loose items ) 
● Parke Davis Opticals envelope 
● Current Board of Visitors 1986-87 
● Members of Board of Visitors Whose Terms Expire This Year 
and Are Not Eligible for Re-election 
● Suggestions for Membership on the Board of Visitors form 
● Letter form Katie Burkett PHSA President to Jiann-Ping Hsu 
College of Public Health Faculty and Staff 
● Top 50 Georgia Foundations by Assets, circa 2003 
● emails from Karl Peace –some links of interest re 
philanthropy 
● Biostatistics 
● Hot Topics in Clinical Trials-white binder 
● Meta-Analysis: fundamentals to Recent Developments-blue 
binder 
● Klonopin Dose Optimization Study – white binder 
● Klonopin Dose Titration Study 
● (loose items) 
● Statistics News printout 
● Update on the Jiann-Ping Hsu College of Public Health 
McNeil Course 
● (loose items) 
● Determining the Optimal Dosage Regimen for H2-Recptor 
Antagonist Therapy-A Does Validation Approach 
● The Pooling of Data from Multicentre Trials 
● The Pooling of Data from Multi-Centre clinical Trials 
● Sample size Considerations in Clinical Trials Pre-Market 
Approval 
● The Impact of investigator Heterogeneity in Clinical Trials on 
Detecting Treatment Differences 
● Statistical Section of a Clinical Trial Protocol 
● TMO: the Trial Management Organization – A New System for 
Reducing the Time for Clinical Trials 
14  3 
DIA 1991  14  4 
Institute For Health, Policy And Evaluation Research  14  5 
Clinical Trial Methodology Book  14  6 
Kidney T.P. Data (L1970, 71970) and ATG Study Data 
● (loose items) 
● Letter from Murl T. Wilson –attached – information regarding 
switch from RX to OTC marketing of Actifed, NDA’s 11-935 
and 11-936 
14  7 
Artifacts/Book Reviews  14  8 
41 
Intrinsic Efficacy to Greg Campbell and Sue-Jane Wang  14  9 
Unlabeled (grey folder) 
● Correspondence between “Brother Kao-Tai” and “Brother 
Karl” regarding joint research 
14  10 
TAS 
● Continuous form stationary 
14  11 
1990 Princeton Conference  14  12 
Calan Site Change Study  14  13 
Articles Needed  14  14 
John Marshall Article 
● (loose items) 
● Past and Present Regulatory Aspects of Drug Development 
● An Overview of the Processes of Discovery, Basic Research, 
Clinical Development, & Manufacturing, In Pharmaceutical 











● Statistical Considerations in the Design and Analysis of H.R.T. 
Study 376-368 
● Drug Development Strategies For Subpopulations 
● Introduction to SAS 
15  1 
Problem with Harsi Patel  15  2 
Special issue of JASA Radio Paper  15  3 
Bioequivalence  15  4 
CIBA Vision Talk  15  5 
History of Biopharmaceutical Section of ASA  15  6 





Statistical Services Department Agenda 
● (loose items) 
● Biopharmaceutical Report Fall 1992 
● Biopharmaceutical Report Fall 2000 
15  8 
FDA Bio equivalency Workshop on Solid Oral Dosage Forms 9/29, 
30, 10/1/86 
15  9 
On the Analysis of Ratios in Bioequivalence Testing 10/5/85  15  10 









● Overview of Clinical Research Data Processing 
16  1 
Workshop on Clinical Trials 12/8-9/83  16  2 
Clinical Trials Workshop for U.K. And European Participants May 31, 
1984 
16  3 
Cumulative Risk Index Seminar Sept 26, 1985  16  4 
Aspects of the Clinical Trials Workshop at Smith Kline and French 
Labs April 19,1983 
16  5 
Finite Markov Chains and Stochastic Processes with Applications: 
Sibbing Gas Diffusion And Chemical Kinetics 
● (loose items) 
● Survey of Frequency of statistical Analyses 
16  6 
Parke Davis: Biometric Standards  16  7 





● A Characterization of the Effect of Varying Sample Sizes, 





● Statistical Analysis Plans (SAP) 
● Issues in Data Monitoring And Interim Analysis In The 
Pharmaceutical Industry 
● Searle Memorandum 
● A Test For Differences Between Treatment Means When 
Several Dose Levels Are Compared With A Zero Dose 
Control 
● The comparison of Several Dose Levels With A Zero Dose 
Control 
● A Non-Parametric Equivalent of Williams’ Test for contrasting 
Increasing Dose Levels of a Treatment 
● Analysis of Data from Multiclinic Trials 
● Statistical Input into the Design and Analysis of Bioavailability 
Studies 
● Organization of Ann Arbor Statisticians Proceedings 
● Sample Compare Program 
● Memo to Biometrics staff from Wayne about Multicenter 
Studies- Are More Subjects Always Better? (Or, What’s the 
Effect of Centers with Few Patients) 
● Standard Analyses - Basic Hypotheses, CLs, and Type 1 Error 
Rates 
Experimental Design by Box & Hunter  16  10 
Biostatistics  16  11 
Meta-analysis Chapter Correspondence  16  12 
Meta-analysis Manuscripts-Peace  16  13 
Unlabeled 
● Methods for Interpreting and Combining Experimental 
Results 
16  14 
On Combining P-U Alues  16  15 
Meta-Analysis Literature Search 
(loose items) 
● Ulcer Disease: Investigation and Basis for Therapy 
● Correspondence between Edward A. Swabb to Karl E. Peace 
● Correspondence between Tom Teal and Karl E. Peace 
● Cost-Effectiveness in treatment of Peptic Ulcer Disease 




● Report of The Workshop on Controlled Release Dosage 
Forms: Issues and Controversies 
16  17 
44 
● Slides on bioavailability 
Karl Peace  16  18 








Perry, M : Health and Wellness in Residents Who Matriculate into 
Physician Training Programs acknowledgement paper 
(loose items) 
● Summary of Gart’s Paper 
● Division of Clinical Pharmacology 
17  1 
Medical College of VA Seminar 2/17/95  17  2 
Clinical Research 
● Hard copies of slides 
17  3 
AJPH Paper: Validity of PH Intervention  17  4 
TTE: Permission verification  17  5 
Contributor Agreements  17  6 
TTE  17  7 
Making Informed consent More Ethical DIA Forum  17  8 
Letter to Editor PHARMA DD  17  9 
Degrees of Freedom in a Nonparametric Test (Letter to 
Editor-Biometrics) 
17  10 





● Research Ethics Timeline 
● The New England Journal of Medicine 
● The New England Journal of Medicine Special Report 
● Teaching Statistics to Medical Students Using 
Problem-based learning: The Australian Experience 
● Fundamentals of Clinical Trials 
17  12 
45 
● Chapter 3 Sample Size Considerations in Clinical Trials 
Pre-market Approval 
● Chapter 8 Clinical Trials in the Treatment of Panic Disorder 










● Biostatistical Aspects of the Analysis and Interpretation of 
Cancer Clinical Trials 
● Monitoring Adverse Experiences in Clinical Drug 
Development 
● The Pooling of Data from Multicentre Clinical Trials 
● Interim Analyses: p-Value and Power Computations in 
Multiple Look Trials 
● Biostatistical Aspects of Development of Drugs to Treat 
Alzheimer’s Disease Based Upon enrichment Designs 
18  1 
Pharmaceutical Classification of Bipolar Disorder” – MCG Seminar  18  2 
MCG MTG re Bipolar  18  3 
Equilibrium-Based Bipolar Neurological Modeling 
(loose items) 
● Practice Guideline for the Treatment of Patients with Bipolar 
Disorder 
● Letter from Karl E. Peace to David J. Kupfer about 
Equilibrium-based Bipolar Dynamic Model 
18  4 
Bio.IT Word  18  5 
DIA  18  6 
Bipolar Conference Pittsburgh 6/8-9/07  18  7 
ICSA – 2007  18  8 











American Society of Hospital Pharmacist (ASHP) Meetings  19  1 
Society for Pharmaceutical Medicine August- September 1988  19  2 
Regulatory Affairs Professionals Society (RAPS) Meetings  19  3 
BRCI Computer Manual  19  4 
Clinical Research Data Processing Book Project  19  5 
American Association of Pharmaceutical Scientist (AAPS) 1989  19  6 
Princeton Conference 1974  19  7 
American Society of Clinical Oncology (ASCO) Meeting 1978  19  8 
Pharmaceutical Manufacturers Association (PMA) Meetings 1978 and 
1989 
19  9 
Gynecologic Oncology Group (GOG) (Phoenix) 1980  19  10 
Second International Conference on Adjuvant Therapy of Cancer 
1979 
19  11 
SUGI (SAS Users Group International) Conference 1981  19  12 
Midwest Biopharmaceutical Statistic Workshop-Muncie Meeting  19  13 
Regional Meeting of Pharmaceutical Statisticians and Data 
Processors 
19  14 
The Scientist Newspaper  19  15 
Pulmonary –Allergy Drugs Advisory Committee 18 th Meeting  19  16 
Third Annual Society For Clinical Trials Meetings  19  17 
Society for Clinical Trials Meetings May 2-5, 1982  19  18 
Society for Clinical Trials May 9-13, 1981  19  19 
Society for Clinical Trails Workshop Proposals for 4 th Annual 
Meeting 
19  20 




Pharmaceutical Industry Statisticians (PIS)  19  22 
American Society for Clinical Pharmacology and Therapeutics 
Booklets March 13-16, 1984 
19  23 
American Society for Clinical Pharmacology and Therapeutics 
(ASCPT) 1984 
19  24 
1984 Spring ENAR Meetings and Orlando American Statistical 
Association (ASA) Meetings Scientific Affairs 
19  25 
1984 Joint Meeting, Philadelphia ASA Annual Joint Meeting Scientific 
Affairs 
19  26 
1985 Spring ENAR Meetings, Raleigh ASA ENAR Meetings Scientific 
Affairs 
19  27 
1985 Annual Joint Meeting, Las Vegas ASA  19  28 
Summary of ASA Biopharmaceutical Section 1985  19  29 
American Statistical Association (ASA) Background and Etiology  19  30 








Equilibrium-Based Bipolar Neurological Modeling  20  1 
Ying-Yang Papers and Research  20  2 
Tacrine/ Alzheimer Papers  20  3 
Summary of the effectiveness of Tacrine  20  4 
ANCOVA Analyses  20  5 
Food and Drug Administration and Peripheral and Central Nervous 
System Drugs Advisory Committee 
20  6 
Population PD/PK  20  7 
Tacrine Meeting 1993  20  8 
Yin Yang Papers and Research 2  20  9 
48 
Ying-Yang Modeling of Bipolar Disorder  20  10 
Yin Yang Dynamic Neurological Modeling and Diagnostic Analysis of 
Major Depressive and Bipolar Disorders 
20  11 
Statistical Methodology of Drug Receptor Theory July 18, 1986  20  12 








1987 Annual Joint Statistical Meetings  21  1 
An Analysis of Data on spontaneous Duodenal Ulcer Recurrence 
and Template 
21  2 
Federal Drug Administration Papers  21  3 
Drug Information Association Workshops  21  4 
Statistical Analysis of Protocol: U20-86-02-005: Comparison of In the 
Treatment of Hypertensive Patients 
21  5 
San Francisco: ASA Joint Seminar Meeting 1987 Workshop: 
Mechanics of Preparing an Integrated Statistical Dual Clinical 
Summary 
21  6 
Draft Guide For the Format and Content of the Statistical Section of 
An Application June 1985 and January 1986 
21  7 
Handbook of Biopharmaceutical Statistics in Human Drug 
Development 
21  8 
Handbook of Biopharmaceutical Statistics in Human Drug 
Development Chapter Contents 
21  9 
Correspondences and Papers 1 1985-1987 
● Correspondences on Chapters in Biopharmaceutical 
Statistics in Handbook of Biopharmaceutical Statistics and 
Drafts 
● American Statistical Association 1984 Proceedings of 
Biopharmaceutical Section 
● Statistics in the Pharmaceutical Industry 
● Letter to Volker W. Rahlfs from Karl E. Peace 
21  10 
49 
Correspondences and Papers 2 1981-1990 
● a. Includes Articles and Drafts of papers with 
Correspondences 
● b. Statistical Issues in Drug Research and Development 
Letters from Sandra Beberman March 22, 1990 
○ i. To Joan Godbee 
○ ii. To Elsie Peace 
○ iii. To Christopher Peace 
○ iv. To Nora Coury 
○ v. To M. T. Roberson 
○ vi. To Mickey Peace 
○ vii. To Karl Johnson 
○ viii. To Ronald Moore 
○ ix. To Walter Lynch 
○ x. To Tom Semler 
○ xi. To Peggy Phillips 
○ xii. To Steve Hutcherson 
○ xiii. To Martha Watson 
○ xiv. Michael Dey 
● c. Statistical Issues for Drug Research and Development No. 
106 
● d. Statistical Issues in Drug Research and Development 
Letter from Marcel Dekker to Karl Peace December 12, 1989 
● e. Statistical Issues in Drug Research and Development Letter 
from Sylvan Wallenstein to Sandra Beberman September 5, 
1989 
● f. Statistical Issues in Drug Research and Development Letter 
from Sylvan Wallenstein to Rebecca Bernstein August 20, 
1989 
● g. List September 18, 1989 
● h. Statistical Issues in Drug Research and Development Fax 
to Sylvan Wallenstein from Sandra Beberman and Preface 
September 18, 1989 
● i. Package Receipt September 6, 1989 
● j. Statistical Issues in Drug Research and Development fax to 
Sylvan Wallenstein from Sandra Beberman August 30, 1989 
● k. Statistical Issues in Drug Research and Development fax to 
Rebecca Bernstein from Sylvan Wallenstein August 20, 1989 
● l. Letter to Sylvan Wallenstein from Karl Peace August 14, 
1989 
● m. A Critique of the Grizzle, Balaam, and White Designs 
August 16, 1983 
● n. A Two Treatment, Two-Period, Crossover Design 
Permitting Assessment of Direct and Carry-Over Effects May 
26, 1981 




● p. Letter to Harji Patel from Karl Peace December 29, 1988 
● q. Statistical Issues in Pharmaceutical Drug Development 
American Statistical Association Sesquicentennial 
Celebration August 6-10, 1989 
● r. Letter to Karl Peace from Harji Patel 
● s. Package Receipt August 14, 1989 
● t. Letter to Rebecca Bernstein from Karl Peace June 22, 1989 
● u. Letter to Karl Peace from Rebecca Bernstein June 21, 1989 
● v. Letters Concerning Statistical Issues in Drug Research and 
Develop 
○ i. To Karl Peace from Rebecca Bernstein August 2, 
1989 
○ ii. To Sylvan Wallenstein from Rebecca Bernstein 
August 2, 1989 
○ iii. To Karl Peace from Rebecca Berstein July 12, 1989 
○ iv. To Karl Peace from henry Boehm July 20, 1989 
○ w. Letter to Karl Peace from Bill July 25, 1989 
● x. Letter to Karl Peace from Donald M. Stablein July 18, 1989 
● y. Letter to Karl Peace from Martha S. Hearron July 21, 1989 
● z. Letter to Karl Peace from Gerald M. Fava 
● aa. Letter to Karl Peace from Morris Meisner July 17, 1989 
● bb. Letter to Karl Peace from Joseph K. Haseman July 25, 
1989 
● cc. Letter to Karl Peace from Lloyd Fisher July 25, 1989 
● dd. Letter July 31, 1989 
● ee. Letter to Karl Peace from Robert Makuch 
● ff. Package Receipt August 2, 1989 
● gg. Analysis of Crossover Designs When the Errors Are Not 
Independent 
● hh. Contract between Marcel Dekker, INC and Karl Peace 
November 17, 1989 
● ii. Contract between Marcel Dekker, INC and Karl Peace 
January 12, 1988 
● jj. Hypothesis Testing for Combination Treatments May 9, 
1989 
● kk. Testing Whether an Identified Treatment is Best May 5, 
1989 
● ll. Statistical Assessment of Combination Drugs 
● mm. Analysis of Crossover Designs When the Errors are Not 
Independent January 30, 1989 
● nn. Loyld Fisher Floppy Disc 
Pharmaceutical Drug Development Statistical Consideration and Art 
July 31, 1989 
21  12 




Correspondence Pertaining to the Publication of ASA Workshop 
Volumes Sesquicentennial Celebration December 29, 1988 
21  14 
Presentations and Guidelines 
● ASA Continuing Education Workshop Preparing the Statistical 
Section Under the New Drug Application (NDA) Rewrite 
August 15, 1987 
● An Outline of the Statistical Section of a New Drug 
Application August 15, 1987 
● Preparing the Statistical Section Under the NDA Rewrite 
● Objective 
● Draft Guideline for the Format and Content of the Statistical 
Section of an Application June 1985 
● Draft Guideline for the Format and Content of the Clinical 
Data Section of an Application January 1986 
21  15 
Correspondences 1986-87  21  16 
Integrated Report  21  17 
Correspondences and Papers 3 
● Correspondences 1985-1990 
● Biopharmaceutical Statistics for Drug Development October 
1987 










● Biostatistical Aspects of Development of H2 Receptor 
Antagonist Drug to Treat Duo Denal Ulcers 
● Biostatistical Aspects of Clinical Research Programs 
● Design and Analysis of Pivotal Trails to Assess Efficacy of 
Drugs to Treat Panic 




● Biostatistical Input to the Design, Analysis and Interpretation 
of Cancer Clinical Trials 
● A Short Course on the Design analysis and Interpretation of 
Cancer Clinical Trials 
22  2 
Transparencies 3  22  3 
52 
● Drug Development Type of Trails 
● Biological Test Systems 
● Clinical Development Biostatics Tutorial 
● Preclinical Safety Development 
● Characterization of a Drug and Its Doses 
Transparencies 4 
● a. Bioassay, Drugs, and Doses 
● b. Clinical Efficacy Trial with Quantitative Data 
● c. Pharmaceutical Lead Discovery and Optimization Drug 
Research October 29-31, 1990 
● d. Placebo Comparisons inactive-Controlled Trials Notes for 
Princeton Conference Tutorial December , 1987 
● e. Draft 
○ i. Biotechnology and Biostatistician 
22  4 
Transparencies 5 
● Genetics and the Future of Medicine 
22  5 
Transparencies 6 
● Corse Outline: Statistical Issues in Drug Research and 
Development 
● Dual Control Groups in Rodent Carcinogenicity Studies 
● Statistical Methods for a Three-Period Crossover Design in 
Which High Dose Cannot be Used First 
● Active Control Equivalence Studies 
● Biostatistical Aspects of the Development of Anti-anginal 
Drugs: A Phase II Trial Incorporating an Equiradial Hexagonal 
Design with RSM 
● Intention to Treat In Clinical Trials 
● Dosing in the Elderly 
22  6 
Julie Achatz/ Klugh  22  7 
Emily Clark/ Klugh  22  8 
Shawna Hedin/ Klugh  22  9 
Rachel Hemberger/ Klugh  22  10 
Olivia McCallum  22  11 
Jon Mann Protocol  22  12 
Diet Product Development  22  13 
Request to Industry  22  14 




● The Center for Rural Health and Research 
● The Use of Nuclear Protein-encoding Genes, RNA 
Polymerase II Tick Molecular Systematics 
22  16 
Correspondences, Schedules, and Check 
● Correspondences 2003 
● Schedules 
● Check from Johnson and Johnson 
● List of names 
22  17 
Transparencies 7 
● Biostatistical Aspects of Development of Drugs to Treat 
Alzheimer’s Disease Based upon Enrichment Designs 
● Analysis and Summarization of Safety Data Collected in 
Clinical Trails 
● The Polling of Data from Multicentre Trials 




● Includes Correspondence September 15, 2000 
● Department of Health and Human Services 
● Preclinical Safety Development 
● Pharmaceutical Formulation Development 
● Biopharmaceutical Statistics for Clinical Drug Development 
22  19 
Papers 
● Clinical Efficacy Trials with Quantitative Data 
● Analysis of Ratios and Decision Rules in Bioequivalence 
Studies 
● Additional Topics 










Paris NSAID Meeting December 5-8, 1987 
● Correspondence December 3, 1987 
● CYTOTOEC (MISOPROSTIL) NSAID Etude Rapport 





Deerhurst Symposium Administration Meeting 
● Comparative Assessment of Spontaneous Relapse Rates 
after Healing Active duodenal Ulcers with Misoprostol or 
Other Agents: A Literature Survey Draft February 16, 1987 
● Acute D.U. 
● Cytotoec Advisory Board meeting November 19-22, 1987 
● The Treatment of Gastric Ulcer with Antisecretory Drug: 
Relationship of Pharmacological Effect to Healing Rates 
Manuscript 
● Duodenal Ulcer What Comes After Healing 
● Smoking and Ulcer Healing Charts 
● Map of Toronto 
● Receipt 
● Correspondence 1986-1987 
● Baseline Description G. D. Searle and Co. Table 1-a 
● Baseline Description G. D. Searle and Co. Table 1-b 
23  2 




Cytotoec Advising Board Meeting November 18-23, 1987 
● Slides 
● Slides Print Outs 
23  5 
Capability of Analyzing Time to Response Data at Burroughs 
Wellcome Co. 
● Seminar March 6, 1980 
○ Printout and Charts 
● Survival Data Analysis User’s Guide 
● BMDPIL Life Tables and Survival Functions Health Sciences 
Computing Facility November 1978 
23  6 
VCU Career Day March 19, 1982 
● Schedule 
● Careers in Statistics 
● Slides Careers in Statistics 
23  7 
PMA Seminars 
● Framed Congratulatory Letters 
○ University of California, Berkeley September 3, 2009 
○ North Georgia College and State University October 
21, 2009 
23  8 




○ Basic Statistics Course 
● Contents 
● Schedule 
Midwest Biopharm. Stat. Workshop May 23-25, 1983 1 




● The PHGLM Procedure 
● Data set for MBSW Example of Repeated Significance 
Testing March 2, 1983 
● Gold Data Salt Lake for Protocol 20 
● Uni-Coll Corporation Expansion of Networking Services 
23  10 
Midwest Biopharm Stat. Workshop May23-25, 1983 2 
● Transparencies 
○ Munclife Study May 24, 1983 
23  11 
Midwest Biopharm Stat. Workshop May23-25, 1983 3 
● Reprographic Services Quality Control Checklist 
● Tables 
● Appendix 2 
● Stepwise Proportional Hazards General Linear Model 
Procedure 1975- 1978 
● Patient Accountability 1973-1983 
23  12 
Analysis of Survival Data Course  23  13 
Non-Sequential Analysis of Time to Event Data Seminar March 1984 




Non-Sequential Analysis of Time to Event Data  23  15 
Non-Sequential Analysis of Time to Event Data Seminar  23  16 
Transparencies 
● Also has paper print form 
23  17 





Reducing Sample Size Through Sequential Analysis 
● Reducing Sample Size Through Sequential Analysis 
Transparencies 
23  20 
Notes on Owner Guide  23  21 
Analysis of Survival Data Course  23  22 
Survival Data Analysis Methodology April 25, 1984 
● NTP Carcinogenesis Bioassay 
● Carcinogenesis Bioassay of L-ASCORBIC Acid (Vitamin C) 






● Statistical Analysis of Protocol U81-86-02-001: Comparison 
of Two Dosing Regimens of Misoprostol as Therapy for 
Duodenal and/or Gastric Ulcer Disease 
23  24 




○ Statistical Analysis of Protocol: U20-86-02-005: 
Comparison of Calan Sr, Tenormin and Capoten in the 
Treatment of Black Hypertensive Patients 
● Statistical Report Outlines 
● Integrated Report 2 
● Integrated Report 3 
23  25 
Research Reports of Clinical Investigation  23  26 
Technical Operations Type Org. 
● Corporate Medical and Scientific Affairs Department of 
Clinical Data Information Management 
● Manager, Clinical Efficiency and Safety Coordination 
● Correspondence 1987 
● Corporate Medical and Scientific Affairs Biometrics 
● 1988 Goals and Strategies 
● 1988 Operating Plan Corporate Medical and scientific Affairs 
● Examination of the Information Management and Analysis 
Requirements of the Scientific Affairs Division of G.D. Searle 










2x2 Crossover Design  24  1 
Correspondences and Papers 
● Papers 
○ The Treatment of Gastric Ulcer with Antisecretory 
Drugs: Relationship of Pharmacological Effect to 
Healing Rates 
○ Protocol Effect of Sleep Reversal on Gastric 
Secretion Before and After a Two Week Period of 
Night-Shift 
○ A Model for Definition of Optimal Dose Size and 
Frequency of Antisecretory Drugs in Duodenal Ulcer 
● Correspondence 1986 




○ iii. Correspondence 1986 
○ iv. The condominium and Timesharing Magazine 
○ v. Information Sheet 
24  2 
Clinical Guideline DIA Workshop May 5-6, 1986 
● Correspondence 1986 
24  3 
DDW San Francisco May 17-22, 1986 
● Correspondence 1986 
● Cimetidine 800mg h. s. in the Treatment of Gastric Ulcer 
● Digestive Disease Week May 18-21, 1986 
● Programs 
24  4 
Influencing Colonoscopy Screening in Rural Southwest Georgia: A 
Pilot Study 
24  5 
Dose Proportions MS.  24  6 
Papers 
● Alternate Solution 
● To the Readers of the American Statisticians 
24  7 
Southwest Georgia Cancer Coalition 
● Agenda 
● Baker County Cancer Screening and Navigation Pilot 
Program Evaluation 




● Baker County Screening and Navigation Project Client 
Demographics January 2006- July 2007 Tables 
● Criteria Rubric for Replication of Baker County Screening 
and Navigation Project 
● Baker County Cancer Screening and Navigation Program 
Evaluation Report 





● Linear Regression Analysis of Censored Data April 11, 1990 
24  10 
Publications AY 07-08 Yin Yang 
● MentalSquare- An Equilibrium-Based System for Biopolar 
Neurobiological Pattern Classification and Analysis 
● JSM 2007 Online Preliminary Program 
● Some Thoughts on the Assessment of Pharmaceutical 
Safety Data 
● List 
● Georgia Public Health Association (GPHA) 78 th Annual 
Meeting and Conference 
24  11 
SAS PC Table Programming 
● Floppy Disks (5 ¼”) 
○ SAS Programs Copied from C Drive m-Mead 
M-MICUSAS… 
○ SAS Tables 
● M_TDEMO SAS B1 VM/IS RELEASE 4.0 CMS 
● M_MCH SAS B1 VM/IS RELEASE 4.0 CMS 
● M_MEANO SAS B1 VM/IS RELEASE 4.0 CMS 
● M_MEAN SAS B1 VM/IS RELEASE 4.0 CMS 
● M_MEANO 
● M_TDEMO 
● Drug vs. Placebo vs. Active 
● Listing of Week 0 Data Set “Derived” 
● M_MCHSAS 
● M_MEAN 
● SAS Table 1 Descriptive Statistics of Seven Primary Efficacy 
Variables at Baseline (B) 
● SAS ® Proprietary Software Release 6.03 
● Fax 1991 
● VSHIELD Version 3.6V77 






● Summary Statistics for TRT BY GLRSPV2 Controlling for 
INVNO 
● % Pagenum Instructions 
● Floppy Disks (3.5”) 
○ Maureen Simmonds Ts. PRN 
○ Untitled (3) 
● The Coding Symbol is for a Thesaurus of Adverse Reaction 
Terms (COSTART) 
● Code (2) 
On Using One Coefficient Variation for Sampling Size Determination  24  13 
Ulcer 
● Usefulness of Anti-Ulcer Drugs for the Prevention and 
Treatment of Peptic Ulcers Induced by Low Doses of Aspirin 
24  14 
What a World Class Community Research Program Would Look 
Like 
24  15 
Design Considerations of Ongoing Trails TTE November 23, 1985 
● Definitions of Risks 
● Design Overview 
24  16 
Design and Cost Considerations of One Trial K Comparisons vs. K 
Trails with one Comparisons 
24  17 
Correspondence and Papers 
● Effect of Two Cimetidine Regimens on Prothrombin Time 
and Warfarin Pharmacokinetic During Long Term Warfarin 
Therapy 
● American Society for Clinical Pharmacology and 
Therapeutics Abstract Form American College of 
Gastroenterology 
● Correspondence 1983; 1989 
● An Evaluation of Triprolidine and Pseudoephedrine in the 
Treatment of Allergic Rhinitis 
● Course/ Colloquy Proposal Form 
● Protocol for Warner-Lambert/Parke-Davis Clinical Trial 
● Warner-Lambert/Parke-Davis Pharmaceutical Research 
Division CI-719-GEMFIBROZIL 
● Levene Test for Homogeneity of Variance 




● Statistical Analysis System July 10, 1978 
24  19 
60 
● Data Female SNRT Data Input 
Wright State University 
● Problems to be Presented in Clinical Session on Biometrics 
● C. R. Rao: Weighted Discrete Distributions 
24  20 
Helsinki Heart Study 
● Helsinki Heart Study: Coronary Heart Disease Incidence 
During an Extended Follow-Up 
● Helsinki Heart Study: An 8.5 Year Safety and Mortality 
Follow-up 
● Correspondence 1992-1993 
● Efficacy of Gemfibrozil in Dysllpidaemic Subjects with 
Suspected Heart Disease. An Ancillary Study in the Helsinki 
Heart Study Frame Population 
● Statistical Analysis Methods for Providing Inferences 
Between Primary Response Measures and Exposure to 
Study Medication in the Helsinki Heart Study: Double Blind 
and Open Label Periods 
24  21 
An Alternative Way of Calculating the X 2 Independence or 
Association Test Statistic for a 2xk Contingency Table 
24  22 
PNAS Manuscripts Review and Revisions 
● Classification: Medical Sciences Tacrine in Alzheimer’s 
Disease: A Population Pharmacodynamic Model for 
Cognitive Effects; Methods, Part 1 of 2 
● Classification: Medical Sciences Tacrine in Alzheimer’s 
Disease: A Population Pharmacodynamic Model for 




● Efficacy Summary File for the Bacteriologic Response Visit 
● Correspondence 1985 
● Data Set M030EFF.DAT 







Non-sequential Analysis of time to Event Data Seminar July 1984  24  26 






Survival Data Analysis Methodology April 25, 1984  24  28 
Colon Carcinoma Exercise 
● Clinical Trial Analysis Colon Rectal Cancer 
● Correspondence 1984 
● Distribution List 













● Survival Data Analysis Correspondence1982-1983 
● Lectures 1-7 
● Independent Study with Bobbi Scueftler 1983 
● VM/SP Conversational Monitor System 
● G.M.T. Was the Origin 
● Lectures 7-11 
● Survival Analysis: Midterm Exam October 20, 1981 MCU 
Biostatistics 
● Re Goodness of Fit 
● Use of the Modified Sauage Statistics in Testing Sequentially 
the Equality of Two Survival Distribution 
● BIS: 600: Final Examination: MCV Richmond, Virginia 23298 
● Analysis of Survival Data Chapters and Biblocist 
● Mortality Table 
● The Mean and Variance of Ŝ LT 
●  Connection Between the Mantel-Haenszel and Cox 
Procedures for Two Sample Case December 17, 1979 
● Test of Hypothesis in 2x2 Tables 
● Situation 
● Computation 
● Marginal Likelihood of Kalbfleisch and Prentice (1973) for 
continuous Time and Non censored Case 
● Test of Significance 
● The Feigl and Zelen Data 
25  1 
Susan Arnold Memorial Project  25  2 
62 
Memorial Shelly Helmstrom  25  3 
Memorial Melissa Giariatataro  25  4 
Memorial Peter Settevendemie  25  5 
Heidi Oh Memorial Consulting  25  6 
Iffath Hogkins  25  7 
Melissa Decker  25  8 
SEGACA: Survey Methodology Group  25  9 
Memorial Consulting: Dr. Eunice Bell  25  10 
Memorial Consulting Michelle Stevens  25  11 
Research Protocol with Bill (William) Hoskins  25  12 
NCIR 25 Grant Norma Sheridan-Leos  25  13 
Comprehensive Screening and Management of Distress Norma 
Sheridan- Leos 
25  14 
Biostatistical Aspects of Clinical Drug Development  25  15 
Chapters 
● Chapter 6 Overview of Bayesian Inferential Methods 
Including Time-to-Event Endpoints 
● Chapter 13 Design and Analysis of Cardiovascular Prevention 
Trials 
● Chapter 14 Design and Analysis of Antiviral Trials 
○ Includes a CD 
25  16 
Maximum Likelihood Estimation and Efficiency Assessments of 
Tests of Hypotheses on Survival Parameters 
25  17 
Eric V. Slud 
● Chapter 5 Overview of Inferential Methods for Categorical 
Time-To-Event Data 
○ Includes a Floppy Disc 
25  18 
Clinical Trials Methodology 
● Clinical Trials Methodology: A Graduate Course in 
Biostatistics for Medical Personnel 
○ Includes Transparencies 
● An Overview of the Processes of Discovery, Basic Research, 





● IV. a: Bioavailability and Bioequivalence of Pharmaceutical 
Formulations 
● The Design and Analysis of Pivotal Clinical Trials to Assess 
the Efficacy of Drugs to Treat Panic Disorder 
● Clinical Trials in the prevention of NSAID Induced Gastric 
Ulceration 
● The Importance of Numbers (of Patients) in Cancer Clinical 
Trials 
● Biostatistical Aspects of the Design of Cancer Clinical Trials 










Framed Photos and Awards 
● Tito Mijares Lifetime Achievement Award 
● Georgia House of Representatives 2008 
● Thank-You Letter 
● Dr. Bill Hoskins 
● Dr. Phil Geetia 
● Letter April 18, 2006 
26  1 
Statesboro Magazine January/February 2011 
● Contains an Article about Karl Peace 
26  2 
PowerPoint Presentations 1 
● Introduction to Design of Genomic Clinical Trials 
● Targeted (Enrichment) Design 
● Categorical Data Analysis using SAS 
● Quantal Bioassay Analysis 
● The Final Session: Recent Topics in Categorical Data Analysis 
● Biomarker Adaptive Threshold Design 
● Development and Validation of Predictive Classifiers Using 
high Dimensional Data 
● Proportional Odds and Generalized Logits Models 
● Weighted Least Squares for Mean Scores 
● Poisson Regression 
26  3 











● Congratulatory Letter from Georgia Southern University 
● Photo of Karl Peace’s Home from Age 10-18 
● Elsie Peace 1974 Sketch of Home Karl Peace (son) was Born 
● Philippine Statistical Association Certificate of Appreciation 
27  1 
BASS Short Courses and Tutorials  27  2 
Magazines 
● Amstat News December 2013-March 2014 
● Newsboy March-April 2014 
● International Chinese Statistical Association January 2014 
● Nature Methods December 2013- March 2014 
● Drug and Development January 2014 and March 2014 
● International BioPharm November 2013- February 2014 
● Applied Clinical Trials December 2013-March 2014 
● Significance December 2013 and February 2014 
● Georgia Back Roads Summer 2012 and Spring 2014 
27  3 
Investing in Public Health 85 th Annual Meeting and Conference of 
the Georgia Public Health Association 
27  4 








● Ernest Karl Peace High School Diploma 1959 
● Vanderbilt University Graduate Summer Session of Statistics 
in the Health Sciences 1975 
● Karl Ernest Peace Clemson University Master of Science 
Degree 1964 
● Thank you from AAPS Atlanta October 1989 
● Alumni Award 
● Omicron Delta Kappa Certificate 2000 
● Letter about the Philippine Statistician’s Tito Mijares Lifetime 
Achievement Award 
● Georgia Southern College Bachelor of Science Degree 1963 
28  1 
65 
● Who’s Who Among Students in American Universities and 
Colleges 1962-63 
● Georgia Southern College Excellent Scholarship 1962 
● Letter about Virginia Commonwealth University’s Founders’ 
Society 
● The Philippine Statistical Association Certificate of 
Appreciation 2004 
● Regulatory Affairs Professionals Society (RAPS) Membership 
Certificate 1989 
● Letter from Jiann-Ping Hsu 
● Letter about Chair-Elect Position from American Public 
Health Association 2009 









o SAS reference books x 7 (Different Volumes and Topics) 
o User’s Guide to Survival Data Analysis 
o Biopharmaceutical Statistics for Drug Development 





o Various magazines mentioning Karl Peace and the JPH College of 
Public Health 
o Auto Auction Magazine 
o Pencil Broadside Sketchbook 











Awards x10  30   









o Idyll’s of the King 
o Key to Robinson’s Progressive Practical Arithmetic 
o Tennyson’s Princess 
o Irving’s Sketchbook 
o Condensed Books (A collection of stories) 
o Course in General Chemistry 
o Trigonometry for Secondary Schools 










● Session 1: Integration of Papln PK/PD Modeling 
● Session 1: Beyond Observational Data Analysis 
● A DIA PK/PD Workshop; Session 1 Basic Concepts and 
Applications 
● Sequence of period Effects 
● Log Transformation for Bioan. Bioeg Data 
● Outlier Analysis 
● A Session II: Individual Ratio Analysis 
● Log Transform 
● Sequence and Period Effects 
● Session IV: Impact on Drug Development 
● Session III: Design for Population PK/PD 
● Session II Modeling and Estimation Tape 2 
● Response to Industry Concerns on Early Termination of 
Clinical Trials 
● Session III: Simple Design Strategies for Poplu PK Model 
● Session II: Modeling and Estimation Tape 1 




● Gardner Communications “Vision” 
● Gardner Communications “Animation” 
● Health Care Industry 













Mathematical physiology: Summary of semester’s work  33  1 
Mathematical physiology: Summary of semester’s work continued  33  2 
Genetics 516 – Population genetics  33  3 
Population genetics continued  33  4 
Topics in Biostatistics  33  5 
ASA course: Analysis of survival data  33  6 
Comprehensives  33  7 
Continuous Form Paper  33  8 
Unbound notes  33  9 
BIY 646 – Nonparametrical statistics – notes  33  10 
BIY 646 – Nonparametrical statistics – problems  33  11 
BIY 600 – Hypothesis testing  33  12 
BIY 600 – Hypothesis testing – Notes, Roll, Reprints  33  13 
BIY 600 – Hypothesis testing – Notes, Roll, Reprints continued  33  14 
BIY 600 – Hypothesis testing – Notes, Roll, Reprints (3) continued  33  15 
BIY 600 – Hypothesis testing – Notes, Roll, Reprints (4) continued  33  16 









30 th Annual Princeton Conference on Applied Statistics  34  1 
Dissertation draft  34  2 
Dissertation – Ch. 4 + 5 (draft)  34  3 
BIY 537 – Sampling theory  34  4 
Statistics 301 – Bayesian Interference  34  5 
Statistics 5020 – Time Series Analysis  34  6 
Statistics 5020 – Time Series Analysis continued  34  7 
Dissertation – Ch. 3 (draft)  34  8 
Exploratory Data Analysis  34  9 
Decision theory – Colloquy 254  34  10 
BIY 511 – Statistical Methods  34  11 
BIY 512 – Experimental design - notes  34  12 
BIY 512 – Experimental design – problems  34  13 
BIY 546 – Linear models – notes  34  14 








BIY 650 – Response Surface methodology  35  1 
BIY 650 – Response Surface methodology continued  35  2 
BIY 650 – Response Surface methodology (3) continued  35  3 
BIY 641 – Advanced inference  35  4 
BIY 641 – Advanced inference continued  35  5 
BIY 642 – Multivariate analysis  35  6 
BIY 642 – Multivariate analysis continued  35  7 
69 
Statistics 300 – Actuarial functions – notes  35  8 
Statistics 300 – Actuarial functions – exercises  35  9 
Math 105 - Finite  35  10 
Colloquy 218 – Methods of Optimization  35  11 
Math 353 – complex variables  35  12 
Math 411 – Linear Algebra  35  13 
Math 453 – Advanced Calculus  35  14 
Math 453 – Advanced Calculus continued  35  15 
Math 371 – Probability  35  16 
Math 503 – Complex variables  35  17 
Math 505 – Problems and verification  35  18 
Math 504 – Complex variables  35  19 
Math 505 – Numerical analysis  35  20 
Math 505 – Numerical analysis – problem assignments  35  21 
Math 505 – Numerical analysis – Solved problem  assignments  35  22 
Math 508 – Fourier Series - notes  35  23 
Math 508 – Fourier Series - solved problems  35  24 
Vector analysis  35  25 
Math 704 – Stochastic processes  35  26 
Math 801 – Linear Hypothesis – notes  35  27 








Math 802 – Linear Hypothesis  36  1 
70 
Math 821 – Real Variables – notes  36  2 
Math 821 – Real Variables – Problems and proofs  36  3 
Math 822 – Real Variables  36  4 
Math 871 – Topology – Notes, Problems, Proofs  36  5 
Math 905 – Decision theory – Problems and proofs  36  6 
Faculty Seminar – Number theory  36  7 
Assorted notes  36  8 
Math 105 – Mathematics for Elementary teachers  36  9 
Statistics  36  10 
Math 110 – Introduction to probability and statistics  36  11 
Math 110 B-D – statistics  36  12 
Math 110 G – Statistics  36  13 
Math 211 Introductory Calculus  36  14 
Math 212 – Introductory Calculus  36  15 
Math 212 – Introductory Calculus continued  36  16 
Math 214 – Multivariable Calculus  36  17 
Math 222 – Math of Finance  36  18 
Math 310 – Differential equations  36  19 
Math 372 – Statistics (first half)  36  20 
Math 372 – Statistics (Second half)  36  21 
Math 402 – Probability  36  22 
Math 403 – Statistics – notes  36  23 
Math 403 – Statistics – solved problems and theorems  36  24 
Math 420 – Vector analysis  36  25 
Math 454 – Advanced Calculus – Ch. 8 outline and proofs  36  26 









Math 872 – Topology and topology seminar  37  1 
Math 891 – Research problems in statistics  37  2 
Math 981 – Mathematical Statistics  37  3 
Diamont Gerson, Cato, Peace and Perkins 
● “An Evaluation of Triprolidine and Pseudoephedrine in the 
Treatment of Allergic Rhinitis” 
37  4 
Holford and Peace Articles 
● “The Effect of Tacrine and Lecithin in Alzheimer’s Disease” 
● “Methodologic Aspects of a Population Pharmacodynamic 
Model for Cognitive Effects in Alzhemer Patients Treated with 
Tacrine” 
● “Results and Validation of a Population Pharmacodynamic 
Model for Cognitive Effects in Alzheimer Patients Treated 
with Tacrine” 
37  5 
Lanza, Peace, Zimmermant Dickson 




● “The Alternative Hypothesis: One-sided or Two-sided?” 
37  7 
Peace Article 
● “Clinical Studies: How to Sucessfully Resolve Clinical 
Problems to Achieve FDA Approval” 
37  8 
Peace Article 













● “Early Termination of Two Trials of Misoprostol in the 
Prevention of NSAID-Induced Gastric Ulceration” 
37  12 
Peace Article 
● “Estimating the Degree of Equivalence and non- Equivalence, 
An Alternative to Bioequivalence Testing” 
37  13 
Peace Articles 
● “The Impact of Investigator Heterogeneity in Clinical Trials on 
Detecting Treatment Differences” 
● “Intention to Treat in Clinical Trials” 
● “The Importance of Numbers (of Patients) in Clinical Trials” 
37  14 
Peace Article 
● “Introduction” (Drug Information Journal) 
37  15 
Peace Article 
● Meta-Analyses in Ulcer Disease 
37  16 
Peace Article 
● “One-sided or Two-sided p Values: Which Most 
Appropriately Address the Question of Drug Efficacy?” 
37  17 
Peace Article 




● Letter to the Editor: “Some Thoughts on One-tailed Tests” 
37  19 
Peace Article 
● “TMO: The Trial Management Organization – A New System 
for Reducing the Time for Clinical Trials” 
37  20 
Peace Article 
● “To Pool or Not (to Pool)?” 
37  21 
Peace and Cannon Articles 
● “Biotechnology and the Biostatistician” x 2 
● Biotechnology and the Biostatistician Slides 
● Biotechnology and the Biostatistician Supplements 
37  22 
Peace and Carter Article 
● “Exposure Analysis of Dichotomous Response Measures in 
Long-Term Studies” 
37  23 
Peace and Flora Article 




Peace and Koch Article 
● “Statistical Methods for a Three-period Crossover Design in 
Which High Dose Cannot be Used First” 
37  25 
Peace and Schriver Article 
● “P-value and Power Computations in Multiple Look Trials” 
37  26 
Peace and Schriver Article 
● “Response” (Journal of Clinical Epidemiology) 
37  27 
Peace and Zimmerman Article 
● “Foreword: Cost-benefit Assessment of Pharmaceutical 
Products” 
37  28 
Randolph, Peace, Seaman, Frank, Dickson and Putterman 
● “Bioequivalence of a New 800-MG Cimetidine Tablet with 
Commercially Available 400-MG Tablets” 
37  29 
Zimmerman and Peace Article 
● “Cost-effectiveness in Treatment of Peptic Ulcer Disease” 
37  30 
BASS Programs  37  31 
Curriculum Vitae  37  32 
Peace Articles 
● “Biostatistical Aspects of the Development of H-2 Receptor 
Antagonist Drugs to Treat Duodenal Disease” 
● “Cimetidine Single-dose Active Duodenal Ulcer Trial” 1985 
● “A Single Nocturnal Dose of Cimetidine in Active Duodenal 
Ulcer” 1985 
● “Efficacy of a Single Nocturnal Dose of Cimetidine in Active 
Duodenal Ulcer” 1985 




● “Biostatistical Aspects of the Development of Anti-anginal 




● “The Pooling of Data from Multicentre Clinical Trials” 
37  35 
Peace Articles 
● “Design Aspects of Cancer Clinical Trial Guidelines for the 
Clinical Evaluation of Antineoplastic Drugs” 1981 
37  36 
74 
● “FDA Requirements for Approval of new Drugs” 
Peace Article 
● Non-sequential Analysis of Time to Event Data 
37  37 
Peace Article 
● Biostatistical Aspects of the Development of Drugs to Treat 
Alzheimer’s Disease based on ‘Enrichment Designs’” 
37  38 
Peace Articles 
● Monitoring Adverse Experiences in Clinical Drug 
Development 
● The Karl E. Peace Lecture Series in Biostatistics 
37  39 
Overview of the regulation of pharmaceuticals, Part 1  37  40 
Overview of the regulation of pharmaceuticals, Part 2  37  41 
Overview of the regulation of pharmaceuticals, Part 2 Continued  37  42 
Processes of pharmaceutical research and development  37  43 
Biostatistical aspects of clinical drug development  37  44 
Assessing bioavailability and bioequivalence studies  37  45 
Analysis of ratios and decision rules in bioequivalence studies  37  46 
Biostatistical aspects of the development of drugs to treat panic 
disorder 
37  47 
Biostatistical aspects of the development of drugs for the 
prevention of NSAID induced gastric ulceration 
37  48 
George – Anne, April 29, 1960  37  49 




Single Subject Spiral Notebook 
● Math 306: Ord. Differential Equations 
37   
Three Subject Spiral Notebook 
● Math 453: Adv. Calculus 
● Math 506: Cal. Of Finite Differences 
37   
75 








Articles 1978 – 1987  38  1 
Articles 1988 – 1991  38  2 
Articles 1992 – 2005  38  3 
Articles 2006 – 2007  38  4 
Articles 2008 – 2009  38  5 
Bibliography of Peace’s Work  38  6 
Disc containing other Peace writings  38  7 
 
Folder 1: (Oversize) Room 2224, Mapcase A- Drawer 15 
 
Karl E. Peace Certificate of Appreciation 1991-1994 
Karl E. Peace Pharmaceutical Manufacturers Association Recognition Award 
Karl E. Peace; Commonwealth of Virginia General Assembly 
Karl E Peace Medical College of Virginia Doctorate Degree 
Poster- Nature Reviews: Molecular Cell Biology 
Poster- Nature Reviews: Cancer 
Poster- Statesboro Magazine October, November 2007 
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